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ABSTRACT
The Hepatitis C Virus (HCV) is a global health problem as it afflicts an estimated 170
million people worldwide and is the major cause of viral hepatitis, cirrhosis and liver can-
cer. HCV is a rapidly evolving virus, with 6 major genotypes and multiple subtypes. Over
the past 20 years, HCV therapeutic efforts have focused on identifying the best-in-class di-
rect acting antiviral (DAA) targeting crucial components of the viral lifecycle, The NS3/4A
protease is responsible for processing the viral polyprotein, a crucial step in viral matura-
tion, and for cleaving host factors involved in activating immunity. Thus targeting the
NS3/4A constitutes a dual strategy of restoring the immune response and halting viral mat-
uration. This high priority target has 4 FDA approved inhibitors as well as several others in
clinical development. Unfortunately, the heterogeneity of the virus causes seriously thera-
peutic challenges, particularly the NS3/4A protease inhibitors (PIs), which suffer from both
the rapid emergence of drug resistant mutants as well as a lack of pan-genotypic activity.
My thesis research focused on filling two critical gaps in our structural understanding
of inhibitor binding modes. The first gap in knowledge is the molecular basis by which
macrocyclization of PIs improves antiviral activity. Macrocycles are hydrophobic chains
used to link neighboring chemical moieties within an inhibitor and create a structurally
pre-organized ligand. In HCV PIs, macrocycle come in two forms: a P1 − P3 and P2 − P4
strategy. I investigated the structural and thermodynamic basis of the role of macrocy-
clization in reducing resistance susceptibility. For a rigorous comparison, we designed and
synthesized both a P1 − P3 and a linear analog of grazoprevir, a P2 − P4 inhibitor. I found
that, while the P2 − P4 strategy is more favorable for achieving potency, it does not allow
the inhibitor sufficient flexibility to accommodate resistance mutations. On the other hand,
the P1 − P3 strategy strikes a better balance between potency and resistance barrier.
The second gap my thesis addresses is elucidating the structural basis by which highly
xvii
potent protease inhibitors function in genotype 1 but not in genotype 3, despite having an
87% sequence similarity. After mapping the amino acids responsible for this differential
efficacy in genotypes 1 and 3, I engineered a 1a3a chimeric protease for crystallographic
studies. My structural characterization of three PIs in complex with both the 1a3a and
genotype 1 protease revealed that the loss of inhibitor efficacy in the 1a3a and GT-3 pro-
teases is a consequence of disrupted electrostatic interactions between amino acids 168 and
155, which is critical for potent binding of quinoline and isoindoline based PIs. Here, I
have revealed details of molecular and structural basis for the lack of PI efficacy against
GT-3, which are needed for design of pan-genotypic inhibitors.
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Chapter I
Introduction
1.1 Hepatitis C Virus
Hepatitis C Virus (HCV) infects an estimated 150 million people worldwide and is the
leading cause of liver cancer and cirrhosis [1]. HCV is highly diverse with six genotypes
(classified 1-6) further subcategorized into different subtypes (a, b, c, etc.) [2, 3]. Different
genotypes have distinct patterns of global geographical distribution. Genotype 1 is the
major genotype in the world, especially in continental America and Europe. Genotype 3,
the second predominant genotype, is mostly observed in Southeastern Asia and countries
including Russia, England and Australia. Other genotypes are relatively minor, but distinct
geographical patterns of spread has been observed: genotype 2 is more dominant in sub-
saharan Africa, genotype 4 in Middle East, genotype 5 in South Africa and genotype 6 in
Asia. These genotypes and subtypes are distinct both genetically and epidemiologically;
relative nucleotide differences are around 30% at genotype level and around 25% at subtype
level [2, 4].
1.1.1 Viral lifecycle and viral proteins
The HCV life cycle consists of entry, uncoating, translation, replication, repackaging
and exit phases. HCV circulates in the host organism in various ways, either in associ-
ation with low-density lipoproteins (LDLs), immunoglobulins or as a free virus particle.
Association of the envelope protein E2 with Tetraspanin (CD81) and Scavenger Receptor
Class B Type I (SR-BI), in combination with LDL receptors (LDL- R), glycosaminoglycans
(GAG), Claudin-I and Occludin, facilitate fusion with human hepatocytes. Upon undergo-
2
3ing clatherin mediated enocytosis [5], the release of viral genome is facilitated by the acidic
environment of the endoplasm [6].
The 9.6 kb genome of HCV encodes an open reading frame (ORF) flanked by 5’ and 3’
highly structured untranslated regions (UTRs). The 5’ UTR contains the internal ribosome
entry site (IRES), which is essential for genome translation. The 3’ UTR plays a key role
in viral propagation. HCV positive sense RNA is translated by the host replication machin-
ery in a cap-independent manner, producing a single polyprotein composed of structural
proteins (Core, E1, E2), p7 and non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A,
NS5B) [7]. The structural proteins and p7 are inserted into the endoplasmic reticulum
lumen and cleaved into functional units by host signal signalases and host signal peptide
peptidases [8]. Subsequent polyprotein processing is perform in cis and trans by the NS2/3
and NS3/4A [9, 10](Fig. 1.1)
4Figure 1.1: Schematic representation of HCV genome
the viral genome is shown with its various structural (blue) and non-structural proteins
(purple) before (A) and after polyprotein processing (B)
5Most of these proteins perform multiple functions required for viral propagation, host
immune suppression and pathogenesis. Core and envelope proteins are an integral part
of the virus particle, forming the viral capsid, facilitating virus–host cell interaction and
infection. Core protein forms the viral capsid that binds the viral RNA [11] and also alters
the host cell lipid mechanism. Highly glycosylated envelope proteins E1 and E2 form
a heterodimeric complex that facilitates host–virus interactions [12]. The p7, a member
of viroporins, has been shown to form oligomeric ion channels in vitro and to be critical
for infectivity in vivo [13] [14] [15]. Non-structural proteins form the viral replication
machinery and are also responsible for packaging of infectious virus particles. NS2 is
implicated in virus assembly and polyprotein processing [16] [17]. In combination with N-
terminal domain of NS3 protease, NS2/3 cysteine protease cleaves the NS2-NS3 junction
[18]. NS3/4A is a multifunctional protease–helicase complex that processes the remaining
viral polyprotein, aids in replication by unwinding RNA in ATP-dependent fashion and
suppresses immune response [16] [19] [20]. NS4A cofactor, an integral part of the NS3/4A
protease, anchors NS3/4A to the membrane and aids in the processivity and translocation
efficiency of NS3 helicase [21] [22]. NS4B is implicated in the formation of membranous
webs, where viral replication happens [23] [24]. NS5A is an essential phosphoprotein
that binds to RNA and implicated in replication, virus assembly and regulation of host
processes [25]. NS5B is the RNA-dependent RNA polymerase that replicates the viral
genome [10].
61.2 Evolution of Standard of Care
Before the advent of direct-acting antivirals (DAAs), the standard of care (SOC) for
HCV infection consisted of pegylated interferonα (Peg-IFN) and/or ribavirin (RBV). Peg-
IFN often causes severe side effects and need to be administered intravenously, causing
patient burden and limiting adherence. As only 40% of patients receiving a 48 week
long Peg-IFN/RBV treatment achieve undetectable viremia post treatment completion, the
urgent need for robust direct acting antivirals was clear.
The first DAA developed against HCV targeted the NS3/4A protease, which is a prime
therapeutic target that is responsible for cleaving the viral polyprotein at diverse sequences
3-4A, 4A4B, 4B5A, and 5A5B and host cell proteins of the innate immune response, in-
cluding TRIF and MAVS [26–28]. Thus, inhibiting NS3/4A serves a dual purpose by
preventing viral maturation and restoring the immune response. The proof-of-concept for
the first direct-acting antiviral (DAA) inhibiting HCV NS3/4A has been provided by the
discovery of BILN-2061 [29] and its ability to reduce plasma HCV RNA levels by 2 to 4
orders of magnitude within 48 hours of treatment [30]. Despite its promise, BILN-2061’s
clinical development was stopped due to toxicity.
Telaprevir (TEL) is a first approved DAA [31, 32]. This NS3/4A protease inhibitor
(PI) is chemically different from BILN-2061, but when administered with Peg-IFN/RBV,
it demonstrated an ability to achieve 67% sutained virological response rates (SVR) [33,
34] with a 36 week treatment duration. Unfortunately, a high percentage of TEL patients
experienced adverse events (21%, vs. 11% for the SOC).
Boceprevir (BOC) is the second HCV DAA to be approved [35]. BOC and TEL share
a common chemical makeup and mode of action. in a SPRINT-1 clinical trial, 70% of pa-
tients receiving BOC/Peg-IFN/RBV for 24 weeks achieved SVR [36]. The clinical success
of both TEL and BOC was challenged by a rapid emergence of overlapping drug resis-
7tance [37].
The next wave of PIs to reach clinical development were asunaprevir (ASV) [38],
simeprevir (SIM) [39], paritaprevir (PAR) [40]), danoprevir (DAN) and vaniprevir (VAN) [41].
All five PIs are approved for clinical use (in the US, Japan or UK) in combination therapies
with other DAAs (NS5B RNA-dependent RNA polymerase and NS5A inhibitors). Thanks
to DAAs, the current HCV SOC is Peg-IFN/RBV free, short in duration (12 weeks) and
efficacious (SVR up to 80–90% depending on genotype) (Fig. 1.2).

91.3 Protease Inhibitors and Drug Resistance
Protease Inhibitors represent the most studied class of DAAs for HCV treatment. Upon
observing that the N-terminal product of substrate sequences acted as competitive inhibitors,
P6−P1 substrate based sequences became the backbone of inhibitor design [42–44]. Con-
sequently, HCV PIs are peptidomimetics that share a common core spanning P3 through
P1, but contain different chemical groups or moieties at the P4, P2, and P1′ positions, and
often contain inter-moiety connections called macrocycles. PIs can thus be categorized in
three broad groups based on their chemical composition and mode of action: linear covalent
inhibitors, linear non-covalent inhibitors, and macrocyclics (Fig. 1.3).
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Figure 1.3: Schematic representation of NS3/4A protease inhibitors
The three broad classes of HCV PIs are shown: linear α-ketoamide covalent (top-black);
linear non covalent (second row-pink); and macrocyclic (P1 − P3 and P2 − P4 in red and
blue respectively.
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The linear covalent inhibitors (TEL, BOC and narlaprevir) take advantage of the NS3/4A’s
catalytic mechanism. Proteolytic activity is carried out by the His57-Asp81-Ser139 cat-
alytic triad via general acid-base catalysis chemistry, whereby the carboxyl oxygens of
Asp81 coordinate the imidazole ring of His57 and positions the former near nucleophilic
Ser139. Through a six-step reaction, the catalytic Ser139 forms a reversible covalent bond
with the enzyme’s substrate. By presenting a carbonyl carbon to the catalytic Ser139, PI can
form reversible protease–inhibitor covalent linkage, which mimics the enzyme–substrate
intermediate state. One major concern with covalent inhibition is off target effects. Proteins
of similar evolutionary lineage often share common tertiary structures and can be inhibited
by the same compound. TEL was reported to also target various host serine protease [45],
representing an added complexity for therapeutic use.
1.3.1 Linear inhibitors
Linear non-covalent inhibitors (asunaprevir, sovaprevir, GS-9451, and faldaprevir) lack
the R2-(C=O) warhead of their covalent counterpart, but instead, contain an extended P2
moiety based on quinolone derivatives. Early structure activity relationship studies of the
P2 motif on a hexapeptide demonstrated improved antiviral activity when bulkier sub-
stituents were used [46, 47]. During the discovery of BILN-2061, the IC50 of Ac-DDIVP-
Nva-OH hexapeptide was improved 21 fold with the addition of a benzyloxy motif at the
γ carbon and by 400 fold with the larger naphthen-1-ylmeth-oxy derivative addition (150
µM, 7 µM, and 0.39 µM respectively) [46]. This naphthalene P2 moiety set the stage for P2
moieties such as quinoline/isoquinoline (asunaprevir), isoindoline (danoprevir-vaniprevir),
and quinoxaline (grazoprevir) [48]. These inhibitors are commonly referred to as 1st gen-
eration, 2nd wave inhibitors because of their low-moderate resistance barrier.
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1.3.2 Macrocyclic inhibitors
In HCV NS3/4A protease, macrocyclic drug candidates come in two forms: linking
P1 − P3 or P2 − P4 (Fig. 1.3). Once again, the discovery of BILN-2061 was fundamental
in the establishing the first example of an HCV macrocyclic inhibitor. Through molecu-
lar modeling of BILN-2061 on the full-length apo NS3/4A, several key observations were
made that led to the development of the P2 − P4 macrocycle: (1) the P2 thiazolylquino-
line moiety packed against a featureless subpocket of the enzyme near residues Asp81,
Arg155 and Asp168. As this moiety significantly increased ligand potency, a nonspecific
interaction could be designed in this pocket; (2) the presence of a unique chemical space
between the P4 cyclopentane and the P2 quinoline ring that could accommodate a hetero-
cyclic connection. Coincidentally, examination of a full-length apo structure showed the
side chain of Glu628 of the N-terminal substrate product overlapped with the proposed
chemical space [49]. Thus the first reported P2 − P4 macrocyclic inhibitor possessed a P2
isoquinoline connected to the P4 carbamate by a six-carbon linker. Subsequent lead op-
timizations gave rise to the discovery of vaniprevir (MK-7009), a subnanomolar inhibitor
with an outstanding pharmacokinetic profile [50]. Up until this point, PIs were performing
well against GT-1 but not so well in non-1 viruses.
Grazoprevir (MK-5172) is a second generation PI, specifically developed to achieve
a broad pan-genotypic activity, and robustness resistance profile [51]. Compared to its
predecessors– VAN, DAN, and SIM– Grazoprevir (GRZ) displays 1 to 3 orders of magni-
tude improvement in both potency and resistance barrier. However, GRZ is not immune to
resistance nor has it shown efficacy against GT-3 virus [51].
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1.3.3 Drug resistance
Lacking a proof reading activity, the NS5B RNA dependent RNA polymerase misin-
corporation rate is estimated to be 10−5 to 10−4 per copied nucleotide [52]. For a rapidly
evolving virus like HCV, this means that of the 1012 new virions produced daily, 91% will
carry no mutation, whereas 8.7% (8.7 billion virions) and 0.42% (4.2 billion virions) will
carry a single or double mutation, respectively [53]. Consequently, infected individuals
will harbor a heterogeneous pool of viruses with diverse genomes, known as quasispecies
[54], where the dominant or wildtype (WT) strain has a high replicative fitness [55, 56].
The diverse pool of quasispecies exists in treatment naı¨ve patients. Once DAA administra-
tion begins, the dynamics of the viral pool change. The selective pressure of the antiviral
quickly eliminates the WT virus in a process known as rapid virological response (RVR)
but fails to affect some mutant variants [57]. Many reports describe the gradual emergence
of drug resistant variants over the course of clinical and in vivo studies; and while sev-
eral viral and host factors contribute to drug resistance, all DAAs are susceptible to drug
resistance [58], including HCV NS3/4A PIs.
HCV protease inhibitors are highly potent against the wildtype GT-1 enzyme with low
nanomolar to subnanomolar affinity, typically reducing the viral load by 3 to 5 orders of
magnitude within 48 hours of PI administration. Despite this remarkable reduction in
viremia, viral breakthrough is observed in all PI based monotherapy and Peg-INF/RBV
combination therapies. Mechanistically, NS3/4A drug resistance arises when a single or
series of amino acid changes occur within the protease leading to an unfavorabe inhibitor
binding, a decrease in inhibitor potency, and a restoration of viral substrate processing (Fig.
1.4).
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The various reported NS3/4A drug resistance mutations cluster in the protease domain
of the bifunctional enzyme in a pattern distinct to the PI’s chemical structure and the en-
zyme’s genotype [59]. For instance, R155K mutation confers resistance to virtually all PIs
in GT-1a but is rarely observed in the GT-1b subtype. Instead, distinct resistance mutations
arise in genotype 1b patients depending on the class of protease inhibitor used: A156 mu-
tates in response to treatment with linear ketoamide protease inhibitors [60–62], whereas
macrocyclic inhibitors more commonly select for D168A and R155K variants [63–66]
(Fig. 1.5). Mutations at V36, T54, and V36+A155 are also associated with resistance to
ketoamide inhibitors [60–62] with R155, A156 and D168 mutations conferring multidrug
resistance. Variations in the patterns of resistance mutations arise from the complex inter-
play between genotype, replication rates, mutation rates, and the resulting effect of muta-
tions on viral fitness and drug potency. Clearly, despite the benefits of combination therapy
in improving SVR rates, the emergence of resistance challenges the long-term efficacy of
NS3/4A protease inhibitors.
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RAVs Mutation Drug(s) susceptible
V36 A,M,L,G Boceprevir, telaprevir
Q41 R Boceprevir, danoprevir
F43 S,C,V,I Boceprevir, telaprevir, danoprevir, simeprevir
V55 A Boceprevir
T54 A,S Boceprevir, telaprevir, grazoprevir
Q80 K,R,H,G,L Simeprevir, asunaprevir, faldaprevir, danoprevir, boceprevir, telaprevir
S138 T Danoprevir, simeprevir
R155 K,T,I,M,G,L,S,Q Faldaprevir, danoprevir, paritaprevir, vaniprevir, sovaprevir, GS-9451,boceprevir, 
telaprevir
A156 V,T,S,I,G Faldaprevir, vaniprevir, simeprevir, grazoprevir, boceprevir, telaprevir
V158 I Boceprevir
D168 A,V,E,G,N,T,Y,H,I Danoprevir, vaniprevir, Asunaprevir, Paritaprevir, Sovaprevir, GS-9451, grazoprevir
V170 A Boceprevir, telaprevir
M175 L Boceprevir
Major NS3/4A protease resistance associated variants (RAVs) in HCV genotype 1
   Active site mutations
Figure 1.5: NS3/4A resistance associated variants
HCV NS3/4A is susceptible to both non active site and active site mutations [59]. Active
site residues 155, 156 and 168 are prone to multi-drug resistance
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1.3.4 Substrate recognition versus inhibitor binding
Drug resistance at the molecular level is a change in the balance of recognition events
between the relative affinity of the enzyme to bind inhibitors versus ability to process sub-
strates. To better understand drug resistance, it is thus important to elucidate the structural
basis for substrate recognition and inhibitor binding to the target protein.
An alignment of the host and viral substrate sequences recognized by the NS3/4A re-
vealed conservation at P1′ (serine), P1 (cysteine), and P6 (acid or small residue); however,
P5 through P2 and P2′ through P4′ displayed a high degree of heterogeneity (Fig. 1.6). As
this heterogeneity rules out amino acid sequence as the substrate recognition motif, a more
careful examination was needed. Crystal structures of HCV NS3/4A protease bound to
peptides corresponding to substrate cleavage sites revealed that, similar to HIV-1 protease,
the substrates adopt a conserved shape defined as the substrate envelope [67]. Active site
resistance mutations occur where the inhibitors protrude beyond this substrate envelope
and contact the protease. Those positions are optimal for multi-drug resistance, as they
are more important for inhibitor binding than for substrate recognition. Most resistance
mutations in HCV NS3/4A cluster around the S2 subsite where the relatively large P2 moi-
eties of PIs protrude beyond the substrate envelope and contact residues R155K, A156T,
D168A, which mutate to confer resistance (Fig. 1.7) [68].
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Substrate P6 P5 P4 P3 P2 P1 P1' P2' P3' P4'
3-4A D L E V V T S T W V
4A4B D E M E E C S Q H L
4B5A E C T T P C S G S W
5A5B E D V V C C S M S Y
TRIF P S S T P C S A H L
MAVS E R E V P C H R P S
Figure 1.6: Alignment of HCV HS3/4A substrate sequences
Genotype 1a NS3/4A viral substrates and host-cell substrates TRIF and MAVS.
Sequences are shown from P6 residues (N-terminus) to P4′ (C-terminus) with conserved
residues highlighted in yellow and scissile bond depicted in red dashed line.
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1.4 Thesis Scope
Therapeutic advances in HCV PIs have generated a wealth of both structure–activity
relationship (SAR) information, and structural perspectives. For instance, extended P2
moieties such as isoquinoline, quinoxaline, and isoindoline are known to have potency
enhancement properties, while the addition of a macrocycle to the inhibitor scaffold reduces
the resistance profile.
This thesis attempts to fill critical gaps in our structural understanding of inhibitor bind-
ing modes as they relate to drug resistance and elucidate the basis for inhibitor failure in
non-1 genotypes, specifically genotype 3. First, I introduce the concept of the structural
basis for drug resistance in HCV protease by comparing the binding mode of ASV to wild-
type protease and the multidrug resistance variant R155K. I demonstrate that very subtle
rearrangements in active site side chains destabilize protease–inhibitor contacts thus reduc-
ing binding favorability. Next, I evaluate the role of macrocyclization in drug resistance by
investigating the structural, dynamic and biophysical basis for enhanced resistance barrier
of a P1 − P3 analogue of MK-5172 relative to the parent MK-5172 and linear analogue.
Next, I investigate the molecular basis for the differential efficacy of PIs in GT-3 relative
to GT-1 by determining the necessary and sufficient amino acid changes to GT-1 protease
to recapitulate GT-3 activity and inhibition. Finally, I present novel strategies for robust
inhibitor design by presenting a structural tool, which compiles our structural knowledge
to predict drug efficacy in GT-3 and well as two novel inhibitor design strategies with
promising applications for broad genotypic targeting.

PREFACE TO : CHAPTER II
This chapter of the thesis has been published in American Chemical Society,
Chemical Biology
Soumana, D., Ali, A., and Schiffer, C. A. Structural Analysis of Asunaprevir
Resistance in HCV NS3/4A Protease ACS. Chem. Biol. 2014 Nov 21;9(11):2485-90.
doi: 10.1021/cb5006118
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DS performed all the experiments, analyses and figure constructions. DS, AA and CAS
interpreted the data and wrote the manuscript.
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Chapter II
Structural Analysis of Asunaprevir Resistance in
HCV NS3/4A Protease
2.1 Abstract
Asunaprevir (ASV), an isoquinoline-based competitive inhibitor targeting the hepatitis
C virus (HCV) NS3/4A protease, is very potent in vivo. However, the potency is signif-
icantly compromised by the drug resistance mutations R155K and D168A. In this study
three crystal structures of ASV and an analog were determined to analyze the structural
basis of drug resistance susceptibility. These structures revealed that ASV makes exten-
sive contacts with Arg155 outside the substrate envelope. Arg155 in turn is stabilized by
Asp168, and thus when either residue is mutated, the enzyme’s interaction with ASV’s
P2 isoquinoline is disrupted. Adding a P1 − P3 macrocycle to ASV enhances the in-
hibitor’s resistance barrier, likely due to poising the inhibitor to its bound conformation.
Macrocyclic inhibitors with P2 extension moieties avoiding interaction with the protease
S2 residues including Arg155 must be chosen for future design of more robust protease
inhibitors.
2.2 Introduction
The hepatitis C virus (HCV) is the causal agent of viral hepatitis, cirrhosis and hepa-
tocellular carcinoma. In the United States, HCV infects an estimated 3.2 million individ-
uals with 17 thousand new cases annually. Globally, the HCV pandemic is a true public
health problem and touches all corners of the world, infecting an estimated 170 million
24
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people [69, 70].
While most of the steps in the viral lifecycle are currently targeted in antiviral therapy,
NS3/4A protease is a key target especially as combination therapy becomes the paradigm
in patient therapy [71]. The NS3/4A protease is a bifunctional enzyme consisting of an N-
terminal serine protease domain, and a C-terminal domain that is a member of the DExH/D-
box helicase superfamily II with ATPase, nucleic acid binding and helicase unwinding
activities. The protease is responsible for processing the viral polyprotein and cleaving
host factors involved in the immune response [27, 72, 73]. Thus, inhibiting the NS3/4A
serves a dual purpose by preventing viral maturation and restoring the immune response.
There are currently three protease inhibitors (PIs) approved by the FDA (boceprevir,
telaprevir, and most recently simeprevir) and several in advanced clinical trails, which are
of a variety of chemical classes. Boceprevir and telaprevir are linear ketoamide compounds
that form a reversible, covalent bond with the catalytic serine of NS3/4A protease [32, 74].
Noncovalent inhibitors include both linear (asunaprevir (ASV) [75], BI 201335 [76]) and
macrocyclic compounds, containing either a P1 − P3 (danoprevir [77], simeprevir [78],
or a P2 − P4 (vaniprevir [50], MK-5172 [79]) macrocycle. However, despite often hav-
ing nanomolar potency against the wildtype (WT) enzyme, drug resistant mutants rapidly
emerge [59]. With the current therapy handicapped by drug resistance, suboptimal pharma-
cokinetics and a lack of cross-genotype activity, the need for robust PIs with high barriers
to resistance is paramount. Drug resistance in HCV NS3/4A is a complex interplay of
molecular events whereby a change in the protease results in a decrease in inhibitor po-
tency while retaining substrate processing and viral maturation. Most HCV PIs have a
common peptidomimetic P1 − P4 scaffold but differ in their P2 moiety. We have previ-
ously shown that the nature of this P2∗ extension moiety, which often protrudes from the
substrate envelope [80], accounts for much of the resistance conferred by single-site mu-
tations at residues Arg155, Ala156, and Asp168. In addition, we have characterized how
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resistance susceptibility and potency of the NS3/4A inhibitors are dependent on both the
P2 extension and the macrocyclization [81].
ASV, a potent linear PI, is currently under development by Bristol-Myers Squibb and in
phase III clinical trials. ASV is chemically characterized by a P1′ acylsulfonamide-linked
cyclopropyl moiety, P2 isoquinoline, and a P1 − P4 pepdidomimetic backbone shared by
most PIs [82]. ASV has promising pharmacokinetics and as monotherapy lowers viremia
by 2.8 to 3.5 orders of magnitude within 48 hours of treatment [83]. However, resistance
challenges ASV due to the rapid evolution of the virus as relapse or viral breakthrough
occurs mid-therapy. R155K, D168G, and I170T conferred low to moderate in genotype 1a
and mutations at D168 conferred high resistance (16- to 280-fold) levels in genetype 1b [82,
83]. Thus, ASV needs to be supplemented with Peg-IFNα/RBV or another direct-acting
antiviral (DAA) [84]. Consequently, understanding ASV’s binding mode in the WT and
multi-drug resistant (MDR) variants of NS3/4A translates into unraveling the molecular
basis for isoquinoline inhibitors’ drug resistance profile and sets the stage for improved
structure-based drug design efforts.
In our previous study, we studied the impact of drug resistance mutations on the po-
tency of ASV and ASV’s P1 − P3 macrocyclic analogue (ASVmc) [81] to WT, R155K,
R155K/V36M, A156T and D168 variants in both enzymatic studies and viral replicon as-
says. Both compounds had extremely good potency in replicon assays with 0.9 and 0.23
nM EC50s, but lost 70/35- (R155K) and 341/84- (D168A) fold in affinity for ASV and
ASVmc, respectively. In this study, we report the crystal structures of WT-ASV, R155K-
ASV and WT-ASVmc complexes. ASV makes extensive intermolecular contacts with the
catalytic residues His57 and Asp81, and the P2 isoquinoline forms an aromatic stacking
on Arg155 with a salt bridge between Arg155-Asp168. Drug resistance occurs when this
electrostatic network is disrupted, thus triggering a domino-like effect to alter the van der
Waals (vdw) contacts, especially at Asp81, and compromises the cation–pi stacking inter-
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action. We also show that adding a P1 − P3 macrocyle to ASV enhances the inhibitor’s
resistance barrier by restraining flexibility to poise the inhibitor for binding. Through a
detailed structural analysis, we describe the atomic basis for ASV’s resistance to R155K
and show how macrocyclizing this inhibitor enhances its resistance barrier.
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2.3 Results and Discussion
To structurally characterize the binding of ASV and assess the impact of mutations and
macrocyclization on drug resistance, the crystal structures of three HCV-NS3/4A genotype
1a protease complexes were determined. These were WT-ASV, R155K-ASV, and WT-
ASVmc, which diffracted to resolutions of 1.66-2.70 A˚, respectively, in the P212121 space
group (Table 2.3.1).
2.3.1 Detailed Structural Analysis of ASV Binding
The HCV NS3/4A inhibitor ASV binds in the active site extensively packing around the
catalytic His57 and Asp81 (Fig. 2.1b) with the P2 isoquinoline moiety stacking both with
the catalytic D81 and R155. ASV makes contacts with 27 protease residues (3 of which
are minor) contributing to a total vdW energy of -44.5 kcal/mol (Fig. 2.2 and 2.3). While
contact with His57 is the most extensive, Asp81, Ser139, Arg155, Ala156, and Ala157
also form extensive contacts, followed by residues 135-137. In contrast Asp168 makes
relatively little direct contact with the inhibitor, suggesting that the large loss of affinity to
the D168A variant results from indirect effects.
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Complexes/crystal WT-ASV R155K-ASV WT-ASVmc
PDB ID 4WF8 4WH6 4WH8
Resolution (A˚) 1.6 1.9 2.7
Space Group P212121 P212121 P21
Molecules in AU 1 1 2
Cell Dimensions
a 39.35 54.92 58.43
b 60.89 58.41 54.96
c 80.87 60.09 59.88
β (◦) 90 90 90
Completeness (%) 92.7 91.7 99.8
Measured Reflections 170394 61851 26199
Unique Reflections 22158 12673 6134
Average I/σ 11.6 (7) 9.2 (4.3) 10.5
Redundency 7.7 4.9 4.3
Rsym (%) 6.8 (31.5) 10 (32) 6.8 (21.2)
RMSD in
Bonds (A˚) 0.013 0.006 0.015
Angles (◦) 1.67 1.5 1.6
Rfactor (%) 19.2 16.8 17.6
Rfree (%) 21.8 21.9 24.8
Table 2.1: Crystallography statistics for HCV NS3/4A–Asunaprevir complexes.
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Figure 2.1: Structural binding mode of ASV and ASVmc
Asunaprevir’s binding mode is reliant on protease S2 residues: structure of HCV NS3/4A
protease in complex with ASV. (a) ASV P2 isoquinoline protrudes from the substrate
envelope (blue volume), interacting with protease S2 residues Arg155 and Asp168
(orange). (b) In the WT complex (PDB id: 4WF8), ASV (orange sticks) engages in
stacking interactions with the catalytic D81 and S2 residue R155. (c) In the R155K
complex (PDB id: 4WH6), Lys155 is no longer stabilized by Asp168, which rotates
toward R123 for electrostatic interaction. Consequently, ASV’s P2 isoquinoline loses
important interaction binding surface (black dashed lines) and is destabilized. (d) ASVmc
(PDB id: 4WH8, pink sticks) adopts a similar binding mode as ASV.
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Figure 2.2: van der Waals contact energy landscape of ASV and ASVmc
vdW contacts are reduced in the drug-resistant mutant structure but maintained in
ASVmc. Surface representation of protease-inhibitor vdW contact energy, where cool and
warm colors indicate low and high vdW energy respectively. (a) In the WT-ASV structure,
high contact energy is exhibited with the catalytic His57, Asp81 and S2 R155, while low
to moderate contact energy is observed in the P1′-P3 pocket. (b) In addition to altering
this energy landscape by reducing inhibitor-protease vdW contacts at Asp81 and Lys155,
the R155K mutation also changes the amino acid packing around Gln41, Val78, Asp168
and Arg123. (c) WT-ASVmc exhibits similar amino acid packing as WT-ASV around the
S2 and P1′-P3 pockets.
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Figure 2.3: van der Waals contact energy of active site residues in ASV/ASVmc
The van der Waals contact energy of protease residues in WT-ASV (blue), R155K-ASV
(yellow) and WT-ASVmc (green) structures, which are mapped onto the structure in the
figure above. ASV’s binding mode is characterized by high vdW contact energy with
catalytic residues His57, Asp81 as well as S2 residues Arg155, Ala156 and Ala157.
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Eleven direct intermolecular and three water-mediated hydrogen bonds (H-bonds) are
formed between the protease and ASV (Table 2.2), in particular at P1′ , P1 and P3 moi-
eties. As in other HCV NS3/4A PIs, the P1′ acylsulfonamide oxygens accept Hbonds from
Ser139 and the oxyanion hole residue Gly137, while the nitrogen (N45) provides a hydro-
gen for His57 Nε2. The ASV P1 carbonyl oxygen accepts three H-bonds from Ser139,
Gly137 and Ser138 while ASV’s P1 amide nitrogen is a donor for Arg155’s backbone
oxygen. Finally, the P3 carbonyl oxygen and amide hydrogen atoms both participate in
H-bonds with the protease Ala157 backbone NH and CO respectively. Additionally, three
hydrogen bonds are formed between neighboring water molecules and ASV’s P2 carbonyl
oxygens, acylsulfonamide oxygens and P4 carbamate oxygen.
Upon binding, ligands often induce conformational changes in the protein. Compared
to the unliganded apo crystal structure (PDB id: 3RC6) [85] such changes are observed
throughout the WT-ASV complex, specifically within the backbone Cα, illustrated by the
presence of major peaks in the Cα distance difference plot (Fig. 2.4). In the WT-ASV
complex, Asp168 has two ionic interactions with Arg155, in contrast to the apo structure of
HCV NS3/4A where Asp168 is rotated away from Arg155 to interact with Arg123 instead
(Fig. 2.5a). Thus in the WT-ASV complex, Asp168 stabilizes Arg155 thereby providing a
binding surface for the isoquinoline and facilitating the aromatic stacking on the catalytic
Asp81.
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2.3.2 Structural Changes Leading to Resistance
ASV is most susceptible to resistance mutations at amino acids 155, 156, and 168.
These amino acids are all located at the NS3/4A S2 binding pocket, where the inhibitor’s
isoquinoline moiety protrudes from the substrate envelope [68](Fig. 2.1a) and interacts
extensively with the protease. In the R155K-ASV structure (Fig. 2.1b), the absence of a
Nε on amino acid 155 prevents Lys155 from interacting with Asp168’s Oδ, thus disrupting
the 168-155 electrostatics, which provides an additional binding surface for the isoquino-
line. As a result, Asp168 shifts towards Arg123 for electrostatic interactions (Fig. 2.5b).
This alteration affects the entire binding interface with ASV as reflected in the altered van
der Waals interactions (Fig. 2.2 and 2.6), while the inhibitor-protease hydrogen bonding
network is maintained (Table 2.2). The extensive disruption of the ASV binding inter-
face in the R155K-ASV complex is in agreement with inhibitor potency drop from 2.7 nM
to 142.7 nM. A similar mechanism may also explain the loss of inhibitor potency in the
D168A variant. While attempts to crystallize the ASV in complex with the D168A variant
were unsuccessful, the interactions of the inhibitor are expected to be significantly dis-
rupted as the Ala168-Arg155 ionic interaction will not exist. Consequently, ASV’s affinity
for the D168A variant drops by three orders of magnitude [81]. This structural resistance
mechanism helps to explain the observed low to moderate resistance patterns in genotype
1a. Resistance to mutations at residues Arg155 and Asp168 is not unique to ASV, but
rather these are signatures of resistance for many NS3/4A inhibitors such as danoprevir,
vaniprevir, sovaprevir and faldaprevir [63, 86, 87]. However, in other genotypes, such as
genotype 1b, the patterns of resistance are altered; for instance, to acquire the R155K mu-
tation two nucleotide substitutions would be required [88], thus genetically altering the
resistance barrier.
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Figure 2.4: Structural impact of ASV macrocyclization
P1 − P3 macrocyclization of Asunaprevir retrains protease conformation: Cα
displacement analysis of inhibitor complexes relative to the unliganded WT protease
(PDB id: 3RC6). The backbone in WT-ASVmc (b) is less disturbed than that in the
WT-ASV complex (a). Mapping the displacement onto the apo protease structure shows
the various secondary structural elements whose conformations are allosterically affected
by inhibitor binding (c and d).
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Figure 2.5: Active site electrostatic network in ASV complexes
Electrostatic network spanning Arg155-Asp168-Arg123 is not conserved in the mutant
structure: (a) in the apo NS3/4A (orange transparent sticks, PDB: 3RC6), Asp 168 is
oriented toward Arg 123 for interactions (grey dashed lines). The WT-ASV complex
(white sticks) has Asp168’s carbonyl oxygens oriented towards Arg155’s nitrogens
forming a salt-bridge (yellow dashed lines). (b) In the R155K complex (white sticks),
Asp168 rotates away from Lys155 and towards Arg123 for interaction, as is observed in
the apo structure. (c) In the WT-ASVmc (white sticks), Asp168’s position enables an
extended salt-bridge formation spanning Arg155-Asp168-Arg123. Both conformers of the
crystal structure are represented.
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Figure 2.6: Change in van der Waals contact energy in ASV complexes
Change in van der Waals contact energy of protease residues with the inhibitor in
WT-ASVmc (black) and R155K-ASV (grey) relative to the WT-ASV structure.
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2.3.3 Improving Asunaprevir’s Resistance Barrier
Although the crystal structure of WT protease with the P1 − P3 ASV macrocyclic ana-
log revealed a similar binding mode to the WT-ASV complex (Fig. 2.1d), several differ-
ences were observed. Compared with the apo structure, the WT-ASVmc complex does not
show as extensive changes in the protease backbone relative to the WT-ASV structure, per-
haps accounting for some of the enhanced binding affinity (Fig. 2.4). Compared to ASV,
the macrocyclic ASVmc has altered vdW interactions at the binding site (Fig. 2.2). Specif-
ically subtle alterations between the structures were observed at P1′ , where the cyclopropyl
group rotates toward the catalytic histidine, the P2∗ proline bears a less puckered pyrroli-
dine ring and the P3 − P4 peptidomimetic bond is displaced out of the active site by 1 A˚.
Within the active site, the major difference lies in the S2 pocket electrostatic network. While
both carbonyl oxygens of Asp168 in WT-ASV are oriented towards R155’s Nε and Nη (Fig.
2.5A), Asp168 in WT-ASVmc rotates by 8.7◦ about the Cα-Cβ-O angle, leading to the for-
mation of an extensive electrostatic network connecting Arg155-Asp168A-Arg123 (Fig.
2.5c).
In agreement with our structural data, ASV and ASVmc displayed similar enzyme inhi-
bition constants with the WT protease (2.6 and 1.2 nM, respectively) [81]. While not signif-
icantly improving potency to the WT protease, the addition of this macrocycle considerably
improved the inhibitor’s resistance barrier. Indeed, all three MDR variants R155K, A156T
and D168A experienced reduced drug resistance susceptibility with lower fold changes in
EC50’s [81]. In the free state, small molecules typically adopt a dynamic ensemble of con-
formations; this is particularly true for those containing proline amide groups, which have
the ability to form cis and trans conformations. The P1 − P3 macrocycle restricts ASVmc
in a trans conformation, thereby potentially decreasing the entropic penalty associated with
conformational reconfiguration required for binding compared to the linear ASV.
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2.4 Conclusion
In summary, asunaprevir is a potent competitive inhibitor targeting the HCV NS3/4A
protease, with clinical and in vitro resistance susceptibility to protease mutations at Arg155,
Asp168 and Ala156. Similar to other inhibitors that we and others have anlyzed [59,68,80],
this resistance profile is the result of the inhibitors reliance on packing to the S2 site residues
including Arg155 beyond the substrate envelope. Avoiding such extensive S2 interactions
and restraining the trans conformation via macrocyclization may be viable strategies to
design inhibitors that are more robust against resistance.
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2.5 Materials and Methods
2.5.1 Protein Handling and Data Collection
Protein expression, crystallization, data collection and processing was performed as
previously reported [68]. Briefly, cells were harvested after 5 hours of expression, pelleted,
and frozen at -80 ◦C for storage. Cell pellets were thawed, resuspended in 5 mL/g of resus-
pension buffer (50 mM phosphate buffer, 500 mM NaCl, 10% glycerol, 2 mM β-ME, pH
7.5) and lysed with a cell disruptor. The soluble fraction was retained, applied to a nickel
column (Qiagen), washed with resuspension buffer, and eluted with resuspension buffer
supplemented with 200 mM imidazole. The eluent was dialyzed overnight (MWCO 10
kD) to remove the imidazole, and the His-tag was simultaneously removed with thrombin
treatment. The nickel-purified protein was then flash frozen and stored at -80 ◦C.
2.5.2 Crystallization
The above-mentioned protein solution was thawed, concentrated to 3 mg/mL and loaded
on a HiLoad Superdex75 16/60 column equilibrated with gel filtration buffer, 25 mM 2-(N-
Morpholino)ethanesulfonic (MES), 500 mM NaCl, 10% glycerol, 30 mM zinc chloride,
and 2 mM 1,4-Dithiothreitol, pH 6.5. The protease fractions were pooled and concentrated
to 20-25 mg/mL with an Amicon Ultra-15 10 kD device (Millipore). The concentrated
samples were incubated for 1 hour with 1-3 molar excess of inhibitor. Diffraction-quality
crystals were obtained by mixing equal volume of concentrated protein solution with pre-
cipitant solution (20-26% PEG-3350, 0.1 M sodium MES buffer, 4% ammonium sulfate,
pH 6.5) in 24-well VDX hanging drop trays.
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2.5.3 Data Collection and Structure Solution
X-ray diffraction data were collected either at Advanced Photon Source LS-CAT 21-
ID-F, at our in-house Rigaku Saturn x-ray system. Diffraction intensities were indexed,
integrated and scaled using the program HKL2000. All structure solutions were generated
using molecular replacement with PHASER [89]. The B chain model of viral substrate
product 4A-4B (3M5M) was used as the starting model for all structure solutions. Ini-
tial refinement was carried out in the absence of modeled ligand, which was subsequently
built in during later stages of refinement. Subsequent crystallographic refinement was car-
ried out within the Phenix program suite [90], with iterative rounds of TLS or restrained
refinement until convergence was achieved. The final structures were evaluated with Mol-
Probity [91] prior to deposition in the Protein Data Bank. To limit the possibility of model
bias throughout the refinement process, 5% of the data were reserved for the free R-value
calculation. Interactive model building and electron density viewing was carried out using
the program.
2.5.4 Structural Analysis
Superpositions were performed in PyMOL using the Cα atoms of the active site pro-
tease residues 137-139 and 154-160. The A chain of WT-ASV complex was used as the
reference structure for each alignment. During the preparation of this manuscript, a WT-
ASV structure (PDB id: 4NWL) similar to our WT-ASV was released [92]. We chose to
use our structure for analysis because of its improved statistics and resolution.
Van der Waals contact energy potential and distance difference plots were determined
as previously described [93, 94].
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Chapter III
Structural and Thermodynamic Effects of
Macrocyclization in HCV Inhibitor Grazoprevir
(MK-5172)
3.1 Abstract
Recent advances in direct-acting antivirals against Hepatitis C Virus (HCV) have led
to the development of potent inhibitors, including MK-5172, that target the viral NS3/4A
protease with relatively low susceptibility to resistance. MK-5172 has a P2 − P4 macrocy-
cle and a unique binding mode among current protease inhibitors where the P2 quinoxaline
packs against the catalytic residues H57 and D81. However, the effect of macrocyclization
on this binding mode is not clear, as is the relation between macrocyclization, thermo-
dynamic stabilization, and susceptibility to the resistance mutation A156T. We have de-
termined high-resolution crystal structures of linear and P1 − P3 macrocyclic analogs of
MK-5172 bound to WT and A156T protease and compared these structures, their molecu-
lar dynamics and experimental binding thermodynamics to the parent compound. We find
that the unique binding mode of MK-5172 is conserved even when the P2 − P4 macrocy-
cle is removed or replaced with a P1 − P3 macrocycle. While beneficial to decreasing the
entropic penalty associated with binding, the constraint exerted by the P2 − P4 macrocycle
prevents efficient rearrangement to accommodate the A156T mutation, a deficit alleviated
in the linear and P1 − P3 analogs. Design of macrocyclic inhibitors against NS3/4A needs
to achieve the best balance between exerting optimal conformational constraint for enhanc-
ing potency, fitting within the substrate envelope and allowing adaptability to be robust
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against resistance mutations.
3.2 Introduction
Hepatitis C virus (HCV) causes chronic liver infection that affects about 3% of the
global population and is the main cause of hepatitis, cirrhosis and liver cancer [1, 69, 70].
HCV has highly error prone replication and therefore is a rapidly evolving, highly di-
verse virus with six known genotypes (gt) and multiple subtypes [2, 3]. Before the recent
availability of direct-acting antivirals (DAAs), the standard of care consisted of pegylated-
interferon (Peg-INF) and ribavirin (RBV) with moderate to low rates of cure across geno-
types and low tolerability [1, 95, 96]. Current efforts aim to determine the best-in-class
DAAs that target several viral proteins including the viral entry protein, the NS3/4A pro-
tease, the NS5A and NS5B non structural proteins [97] and host microRNAs [98] either
individually or in combination. Four FDA-approved HCV inhibitors (telaprevir [31, 32],
boceprevir [35], simeprevir [39], and most recently, paritaprevir [40]) target the NS3/4A
protease. The NS3/4A protein is a bifunctional enzyme containing an N-terminal serine
protease domain (amino acids 1–180) with the classic catalytic triad (S139, H57, D81) of
the chymotrypsin superfamily, and a C-terminal DExH/D-box helicase of superfamily II
with NTPase activity [99–102]. The NS3/4A protease is responsible for cleaving the viral
polyprotein and host factors involved in the innate immune response, including TRIF and
MAVS. Thus, targeting the NS3/4A protease achieves a two-pronged attack on the virus by
preventing viral maturation and restoring the immune response [26, 27, 72, 103].
As the HCV NS3/4A inhibitors are a key component of combination therapy and in-
creasing the cure rate across HCV genotypes, many more are currently in advanced clinical
trials. Among these inhibitors, MK-5172 stands out with relatively high pan-genotypic
potency [51]. MK-5172 shares the same peptidomimetic core P1′ -P3 scaffold as several
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other HCV PIs (danoprevir, asunaprevir and vaniprevir) but is distinct in its P4 capping,
P2 quinoxaline moiety connected to the P2 proline via an ether linkage, and finally, its
P2 − P4 macrocycle (Fig. 3.3.1 A) [49, 79]. While the majority of NS3/4A inhibitors are
susceptible to single site mutations R155K, A156T and D168A, MK-5172 is more robust
against resistance with the exception of A156T in vitro [51, 68]. These single site muta-
tions are able to confer resistance to most inhibitors, depending mostly on the inhibitor P2
moiety [51, 68, 81]. The large P2 moiety of inhibitors protrude out the substrate envelope
and extensively contact R155 and D168 residues that mutate to confer resistance [68, 80].
The co-crystal structure we determined showed that MK-5172 thwarts resistance at these
sites as the P2 quinoxaline moiety largely interacts with residues of the catalytic triad [68].
This binding mode explains MK-5172’s relatively high potency against R155K and D168A
and provides a unique barrier to resistance, as the catalytic residues cannot mutate without
compromising proteolytic activity.
Another distinct chemical feature of MK-5172 is the macrocycle that connects the P2
quinoxaline moiety to the P4 capping group. Macrocyclization is a general strategy em-
ployed to increase inhibitor potency in a wide array of drug targets [104, 105]. By intro-
ducing a conformational constraint to the inhibitor, the structure can be pre-organized in
a binding-competent conformation to decrease the entropic penalty associated with target
association. However the effect of macrocyclization on the energetics of binding for MK-
5172 has not been quantified. In fact, there is no previously published data on the thermo-
dynamics of binding for any active-site/ competitive HCV protease inhibitor. For NS3/4A
protease, we have previously found by enzymatic and antiviral assays that P1 − P3 and
P2 − P4 macrocyclic inhibitors are more potent compared to their linear analogs, and that
the location of macrocycle significantly affects resistance profiles [81]. In particular, the
P1 − P3 macrocyclic analog of MK-5172 is more robust against the A156T resistance mu-
tation, however whether the unique binding mode on the catalytic triad is retained and the
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thermodynamic and energetic implications of alternative macrocyclization status were not
known.
To elucidate the structural basis of resistance and activity for MK-5172, its linear (5172-
linear) and P1 − P3 macrocyclic (5172-mcP1 − P3) analogs (Fig. 3.3.1A) and their sus-
ceptibility to A156T, we determined high-resolution inhibitor co-crystal structures with
both WT and A156T mutant genotype 1a NS3/4A protease domain. In addition to analyz-
ing the structures of the six protease–inhibitor complexes, we determined how binding ener-
getics and conformational dynamics change with macrocyclization status using calorimetry
and molecular dynamics simulations. We find that the unique binding mode of MK-5172
is independent of the macrocycle, and that the rigidity imposed by the P2 − P4 macrocycle
prevents inhibitor rearrangement to be able to efficiently accommodate the A156T muta-
tion. The flexibility of the linear analog allows subtle conformational rearrangements to
accommodate the mutation but the associated entropic disadvantage results in lower po-
tency. Lastly, 5172-mcP1 − P3 benefits from the entropic advantage of macrocyclization
while still allowing conformational rearrangements to reduce susceptibility to A156T. The
preservation of the parent compounds binding mode in the absence of the P2 − P4 macro-
cycle provides further opportunities to optimize this class of inhibitors, while avoiding
known sites of drug resistance.
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Inhibitors 5172-mcP1 − P3 5172-Linear
Complexes WT A156T WT A156T
PDB Code 5EPN 5EPY 5EQQ 5ETX
Resolution (A˚) 2.3 2.3 1.6 2.3
Space Group P212121 P212121 P212121 P21
Twin Law - - - -k,-h,-l
Twin Fraction (%) - - - 0.1
Molecules in AU 1 1 1 4
Cell Dimensions
a 55.2 54.9 54.71 65.4
b 58.5 58.4 58.42 63.2
c 60.1 60.0 59.96 92.3
β(◦) 90 90 90 91.6
Completeness (%) 96.2 99.9 99 99.9
Measured Reflections 38720 39511 156955 129154
Unique Reflections 8793 9070 23941 31801
Average I/sigma 9 9.1 9.1 18.4
Redundancy 4.4 4.1 6.6 4.1
Rsym (%) 6.7 (18.1) 6.8 (20) 7.9 (32.9) 7.2 (11.3)
RMSD in
Bonds (A˚) 0.005 0.011 0.014 0.015
Angles (◦) 1.3 1.3 1.7 1.7
Rfactor (%) 15.2 17.3 16.3 20
Rfree (%) 19.9 21.6 19.7 25.4
Table 3.1: Crystallographic statistics of MK-5172 analogs
Structural comparison was performed with 3SUD (WT–MK-5172) and 3SUD
(A156T–MK-5172)
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3.3 Results
We have determined high-resolution crystal structures of MK-5172 analogs in complex
with the WT genotype 1a NS3/4A protease and A156T variant (WT–5172-linear, A156T–
5172-linear, WT–5172-mcP1 − P3 and A156T–5172-mcP1 − P3) (Fig. 3.1). Three of
these structures are in the same P212121 space group while the A156T–5172-linear is
in P21 with four molecules in the asymmetric unit (only one molecule was chosen for
analysis; see Materials and Methods). These four new and the two previously determined
crystal structures of MK-5172 (PDB IDs 3SUD and 3SUG, for WT and A156T variants, re-
spectively) [68] were analyzed comparatively, specifically for details of inhibitor–protease
interactions.
3.3.1 The unique binding mode of MK5172 is independent of the macro-
cycle
Unlike all other HCV PIs with known co-crystal structures, MK-5172 interacts with
the catalytic triad in a unique conformation where the P2 quinoxaline moiety packs largely
against the catalytic residues H57 and D81 (Fig. 3.3.1) . The P1 − P4 peptidomimetic
inhibitor scaffold spans the S1 − S4 binding pockets interacting with the carbonyl oxy-
gens of R155 and A157 as well as the N of A157. The P1′ acylsulfonamide is positioned
in the oxyanion hole and hydrogen bonds to H57, G137 and S139. This binding mode
is unchanged when the P2 − P4 macrocycle is removed (5172-linear) or replaced with a
P1 − P3 macrocycle (5172-mcP1 − P3). Therefore the binding mode of MK-5172 is a
function of the P2 moiety rather than the macrocycle.
Despite conservation of the overall binding mode, the potency of MK-5172 and its
analogs vary greatly against WT and A156T variants [68, 81]. MK-5172 inhibits WT pro-
tease with aKi of 0.14 nM, lower than those of linear and P1 − P3 analogs (9.5 and 2.0 nM
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respectively), but loses 74-fold potency against the A156T variant. The P1 − P3 and lin-
ear analogs lose 29 and 230-fold potency against A156T relative to WT protease. To gain
insights into the molecular basis of this difference, next we analyzed how the details of
protease–inhibitor interactions are affected by the macrocyclization status and the A156T
drug resistance mutation.
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Figure 3.1: MK-5172 and analogs binding to HCV NS3/4A protease
(A) The chemical structures of MK-5172, 5172-mcP1 − P3 and 5172-linear. The P1′ to
P4 moieties are indicated on the MK-5172 structure. Binding of the compounds at the
active site in (B) WT and (C) A156T protease. The absence of the P2 − P4 macrocycle
does not disrupt the P2 quinoxalines interactions with the catalytic aspartate/histidine
residues. The catalytic triad is highlighted in yellow, R155 in blue, D168 in green and
A/T156 in red.
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3.3.2 A156T alters the packing of the macrocyclic analogs at the active
site
To analyze the details of inhibitor packing at the active site, the relative van der Waals
(vdW) interaction energies between the inhibitor and protease residues in the crystal struc-
tures were calculated (Fig. 3.2 and 3.3). In line with the conservation of the overall bind-
ing mode, the strongest inhibitor–protease interaction occurs with the catalytic H57 and
D81 in all WT complex structures (Fig. 3.2B), with similar total vdW interaction energies
(WT–MK-5172: -43.2, WT–5172-linear: -42.3, WT–5172-mcP1 − P3: -45.1 kcal/mol).
Nevertheless, there are subtle alterations in the details of inhibitor packing. For instance,
compared to the parent compound, vdW interactions with D81 are 0.8 kcal/mol weaker
in the linear analog, indicating subtle changes in the stacking of the P2 quinoxaline moi-
ety. In addition, inhibitor contacts with R155, Y56 and Q41 are weaker in the analogs
compared to the parent MK-5172, in agreement with decreased potency against the WT
protease (Fig. 3.3).
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Figure 3.2: Surface representation of van der Wals contacts in MK-5172 analogs
Changes in the packing of the inhibitors due to A156T at the HCV NS3/4A active site
evaluated by the vdW contact energies. (A) Superposition of the inhibitor bound to WT
and A156T protease. The vdW contact energy with the inhibitor mapped onto the protease
surface in (B) WT and (C) A156T variants. The warmer (red) and cooler (blue) colors
indicate more and less contacts with the inhibitor, respectively.
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Figure 3.3: van der Waals contact energy of protease–inhibitor interactions
(A) van der Waals contact energy of active site resides in MK-5172 (orange),
5172-mcP1P3 (magenta) and 5172-Linear (blue), with wild type and A156T complexes
shown in dark and light shading, respectively. (B) Changes in vdW potential observed in
A156T complexes relative to wild type.
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The primary drug resistance mutation A156T alters packing of MK-5172 and its analogs
at the active site to varying extents (Fig. 3.2C). In complexes with the mutant protease, the
inhibitor needs to rearrange to avoid a steric clash with the larger Thr sidechain. In the WT
complex conformation, the P2 − P4 macrocycle of MK-5172 would sterically clash with
the larger Thr sidechain. As a result, the entire inhibitor shifts relative to the WT com-
plex in the A156T–MK-5172 structure, with the macrocycle moving away from residues
R155, A157 and the P2 quinoxaline away from D81 toward the catalytic histidine (Fig.
3.2, 3.4). We have previously described this steric effect as the molecular mechanism be-
hind MK-5172’s susceptibility to A156T [68]. When the P2 − P4 macrocycle is removed,
the shift due to the A156T mutation is much more subtle with the 5172-linear’s P2 quinox-
aline maintaining stacking interactions with H57 and D81. Instead, the P4 tert-butyl moiety
adapts a different conformation to accommodate the larger Thr sidechain and loses packing
against residues 155 and 156, but establishes more contacts with residues 157–159. Simi-
larly, in the A156T–5172-mcP1 − P3 complex, rearrangement of the P4 moiety is able to
accommodate the larger Thr sidechain to avoid a steric clash without severely compromis-
ing the stacking interactions of the P2 quinoxaline. Overall, 5172-mcP1 − P3 maintains
WT-like contacts at the protease active site with the exception of decreased packing against
D81, but to a lesser extent than that of the parent MK-5172. Hence, 5172-mcP1 − P3
analog benefits from stabilization by the P1 − P3 macrocyclization without paying a steric
penalty due to the Thr mutation at position 156.
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Figure 3.4: Inhibitor packing at the active site in HCV NS3/4A protease crystal structures
(A) Relative van der Waals interactions of P1′ − P4 inhibitor moieties (B) changes in vdW
interactions in A156T relative to WT protease.
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3.3.3 Active site hydrogen bonding pattern is dependent on the macro-
cyclization status and gets disrupted with A156T mutation
Unlike in the apo state or when binding weak ligands, high-affinity substrates and in-
hibitors stabilize an extensive electrostatic network at the HCV protease active site, in-
volving sidechains of protease residues D81, R155, D168, and R123 [68, 85]. Within this
network, R155–D168 interaction is particularly key for maintaining an electrostatic surface
that accommodates high-affinity ligand binding [106]. This interaction is present in all WT
complex crystal structures with two hydrogen bonds (H-bonds) between the sidechains of
R155 and D168 (Fig. 3.5 and 3.3). In the A156T–MK-5172 protease complex, however,
R155 loses both these H-bonds and D168 instead interacts with R123. A similar rearrange-
ment of sidechains underlies the resistance mechanism of asunaprevir to R155K mutation
[106]. Mutation of A156, while not directly part of this electrostatic network, still results in
a similar disruption of the active site binding surface in the MK-5172 complex, correlating
with MK-5172’s susceptibility to A156T.
To assess the stability of the active site hydrogen bonding, we calculated the average
time H-bonds were observed during the molecular dynamics (MD) simulations. Although
present in the MK-5172 crystal structure, the H-bonds between D168–R155 does not per-
sist during the MD simulations, suggesting that this interaction may not be critical to high-
affinity inhibitor binding. In contrast, the sidechains of R155 and D168 form highly stable
H-bonds in all WT complexes (present more than 89% of the time), consistent with its
key role in optimal active site electrostatics. The MD simulations also revealed the persis-
tence of protease–inhibitor H-bonds over time, elucidating the relative bond stability and
overall contribution to intermolecular interactions. Most intermolecular H-bonds are at the
P1 − P1′ moieties (Fig. 3.5 and 3.2), where the inhibitors also have strong vdW interac-
tions with the active site (Fig. 3.2A). Although the hydrogen-bonding patterns of the three
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analogs with the active site residues are very similar in the complex crystal structures (Ta-
ble 3.3), the stability of specific H-bonds varies (Fig. 3.5). MK-5172s P1 amide N forms
a H-bonds with R155 (83% time). This interaction is lost in 5172-mcP1 − P3 but present
in 5172-linear (68% time). At the P1′ moiety, MK-5172 forms four H-bonds with H57,
S139 and G137 (77%, 63%, 38% and 52%, respectively). 5172-linear forms the same four
H-bonds as MK-5172 but at a higher frequency (50%, 87%, 90% and 86%). This improved
stability of H-bonds in 5172-linear correlates with the more favorable enthalpy of binding
seen in 5172-linear relative to both macrocyclic analogs (Fig. 3.6A).
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The presence of the A156T drug resistance mutation considerably alters the network
of hydrogen bonding patterns at the active site. Just as in the crystal structure, during
the MD simulations the A156T–MK-5172 complex loses R155–D168 interactions for the
less stable D168–R123 H-bonds (97% and 89% versus 60% and 56%, respectively) (Fig.
3.5C). In contrast to the parent compound, both 5172-mcP1 − P3 and 5172-linear analogs
maintain the key R155–D168 H-bonds (Fig. 3.5A), which partially correlates with the
lower fold-loss in potency due to A156T mutation.
Compared to the protease active site changes, loses in intermolecular hydrogen bonding
in the mutant complexes are more pronounced across all three inhibitors. MK-5172 loses
all H-bonds at P3 and P1, and has a weaker P1′ amide N–H57 interaction. 5172-linear
experiences the worst drops in H-bonds stability, affecting all of its intermolecular interac-
tions. 5172-mcP1 − P3, while experiencing decreases in H-bonds stability throughout the
inhibitor, is able to maintain WT-like interactions. The A156T drug resistance mutation
therefore has a disruptive effect on both inter and intramolecular hydrogen bonding, how-
ever, the inhibitors macrocyclization status can differentially attenuate this effect. Overall,
the P1 − P3 analog is able to maintain a more WT-like hydrogen-bonding pattern.
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3.3.4 Enthalpic loss due to A156T underlies differences in inhibitor
susceptibility
The thermodynamics of protease binding for MK-5172 and its analogs were assessed
to interrogate the underlying energetic effects of macrocyclization on inhibitor potency
and susceptibility to A156T mutation (Fig. 3.6A and Table 3.4) using isothermal titration
calorimetry. Although a weaker binder, interestingly the linear analog had more favorable
enthalpic interactions. The macrocyclic analogs MK-5172 and 5172-mcP1 − P3 have a
more favorable (negative) entropic contribution than 5172-linear (-T∆S of -6.6 and -6.0,
respectively compared to -3.1 kcal/mol) in binding WT protease, presumably due to the
lack of entropic penalty from the rigidity of the macrocyclization. This enhancement in
entropy more than compensates for the decrease in the enthalpy of binding, underlying the
increased potency of macrocyclic inhibitors compared to their linear counterparts.
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B) WT–MK-5172
WT–5172-mcP1P3
A156T–5172-LinearWT–5172-Linear
A156T–MK-5172
A156T–5172-mcP1P3
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Entropy (-TΔS)
Enthalpy (ΔH)
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Flexible Rigid
Figure 3.6: Energetic and dynamic effects of macrocyclization on inhibitor binding.
(A) The entropy and enthalpy of binding of MK-5172 and analogs to WT and A156T
protease variants. (B) The dynamic inhibitor envelope when bound to WT and A156T
protease. Red and blue indicate less and more flexible regions of the inhibitor,
respectively.
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All three inhibitors lose considerable potency in the presence of the A156T mutation
compared to binding the WT protease. The entropic loss due to this mutation is similar for
all inhibitors (2.2, 3.3 and 2.3 kcal/mol for MK-5172, 5172-mcP1 − P3 and 5172-linear,
respectively Table 3.4), suggesting the loss may be partially related to the greater loss in
the degrees of freedom of the larger Thr sidechain compared to Ala. Unlike entropy, the
enthalpic changes vary greatly among the three inhibitors (2.7, -0.5 and 1.1 kcal/mol for
MK-5172, 5172-mcP1 − P3, and 5172-linear, respectively Table 3.4) and largely corre-
late with the changes in inhibitor packing presented above, and susceptibility to A156T.
Although 5172-mcP1 − P3 loses similar amount of entropy due to the A156T mutation,
unlike the parent MK-5172, the enthalpic contribution to binding actually is better (-5.8
and -6.3 kcal/mol, respectively for binding WT vs. A156T protease). 5172-mcP1 − P3
can better accommodate the larger Thr sidechain to enhance inhibitor packing at the active
site, which results in maintaining the favorable binding enthalpy and hence potency against
A156T. Thus binding thermodynamics is consistent with the steric clash of A156T with
MK-5172 causing the greatest loss of affinity.
3.3.5 Enzyme and inhibitor conformational dynamics correlate with
binding thermodynamics
To further access the impact of A156T mutation on inhibitor binding and reveal any dy-
namic changes in the complexes underlying potency loss, we carried out fully solvated and
extensive MD simulations of all six complexes starting from each of the crystal structures
we determined.
The dynamics of inhibitors bound to the protease were assessed by the dynamic in-
hibitor envelope [107], which can be visualized as a probability distribution for inhibitor
occupancy at the active site during MD trajectories (Fig. 3.6B). When the inhibitor is
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rigid the occupancy is high (red), while more flexible moieties sample different confor-
mations resulting in low occupancy values (blue). The conformational flexibility of the
bound inhibitor can affect both the entropy and enthalpy, and we find that the changes in
flexibility mostly correlate with the enthalpy of binding. Comparing the two macrocyclic
inhibitors binding to the WT protease, MK-5172 is more rigid and maintains more stable
inter-molecular interactions, which correlates with its more favorable enthalpy compared
to 5172-mcP1 − P3. In the presence of the A156T mutation, these interactions are desta-
bilized resulting in a less occupancy (more blue) dynamic inhibitor envelope, and worse
enthalpy of binding for MK-5172 (-6.8 versus -4.1 kcal/mol). This destabilization is less
pronounced for the P1 − P3 analog (more rigid (or red) in (Fig. 3.6B), which maintains its
enthalpy of binding. As expected, the linear analog is more flexible even in the bound state
in the WT complex compared to the macrocyclic analogs. However, the linear analog pays
a higher entropic penalty upon binding due to the lack of a macrocycle constraining con-
formational flexibility in the free state (as revealed by the smaller magnitude of favorable
entropy than those of the macrocyclic compounds). However, although not favorable for
entropic considerations, the lack of a macrocyclic constraint allows 5172-linear to adapt
to the mutated surface for optimal packing. This adaptation likely results in the largely
maintained favorable enthalpy of binding (6.9 kcal/mol) in the presence of A156T muta-
tion. Indeed, MD simulations revealed that the linear analog adapts to the A156T mutation
by sampling a substantially different conformation than that in the WT complex or the
starting crystallographic binding pose (Fig. 3.11). By sampling this alternate conforma-
tion, 5172-linear sacrifices entropically favorable flexibility of the P2 group in the bound
state, resulting in a high-occupancy (red) dynamic inhibitor envelope (Fig. 3.6B). Hence,
alterations in conformational flexibility and related changes in the entropy and enthalpy of
binding due to A156T depend on the macrocyclization status of the analogs.
In addition to inhibitor flexibility, the backbone dynamics of the protein were assessed
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by Cα root mean square fluctuations (RMSF) during the MD simulations (Fig. 3.7 and
3.10). Nine highly flexible structural regions were identified: (1) the N-terminal NS4A
linker, (2) α0 helix spanning residues 12–15, the loops (3), (5), (7) and (8) spanning
residues 37–43, 67–72, 88–93 and 157–163 respectively; (4) α1 helix spanning residues
56–61 and containing the catalytic His; (6) F1 β strand spanning residues 76–82 and con-
taining the catalytic Asp; and (9) the C terminal α3 helix spanning residues 173–179. These
flexible regions mainly correspond to turns/loops or terminal portions of secondary struc-
tural elements throughout the protein structure. The WT protease displays similar backbone
dynamics with flexible N and C termini and a stable core when bound to MK-5172 and the
two analogs. However, the introduction of the A156T mutation alters these dynamic sig-
natures. In MK-5172 (Fig. 3.7 and 3.10A), the A156T variant increases the backbone
flexibility at the N-terminus as well as regions 2, 3, 4, 6, 7 and 8. In 5172-mcP1 − P3 com-
plex (Fig. 3.10B), the A156T mutation has the opposite effect of reducing flexibility, in
particular at regions 1 and 3, relative to the WT complex. As the P1 − P3 macrocycle does
not sterically clash with the larger Thr sidechain, the backbone fluctuations of the mutant
complex are not considerably affected by this mutation. In 5172-linear (Fig. 3.10C), the
A156T mutation perturbs the backbone Cα at the N and C termini as well as at regions 2,
3, 6, 7. Thus, the mutation causes disturbance to the protein backbone dynamics both at
and away from the active site in complexes of MK-5172 and the linear analog, while the
protease dynamics is more robust against the dynamic effects of the mutation when bound
to the P1 − P3 analog. Overall, changes in both inhibitor and protease dynamics underpin
the observed impact of A156T mutation on the thermodynamics of binding and loses in
inhibitor affinity.
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3.4 Discussion
The high potency of MK-5172 (sub-nM for WT protease) and robustness to R155K
and D168A mutations depend on MK-5172s unique binding mode where the P2 quinox-
aline moiety packs against the catalytic H57 and D81. Albeit beneficial for potency, the
P2 − P4 macrocycle can be regarded as MK-5172s Achilles heel as the rigidity of this re-
gion sterically clashes with the multidrug-resistant (MDR) mutation A156T resulting in
3800 fold change (FC) in Ki relative to WT. However, whether the macrocycle could be
removed without affecting the binding mode was unclear. In this study the structural and
thermodynamic analyses were probed with the linear and P1 − P3 analogs of MK-5172 we
previously designed [81], revealing that macrocyclization does not alter the packing of the
quinoxaline moiety but influences susceptibility to the A156T mutation.
The HCV NS3/4A protease structure has an extensive electrostatic network at the ac-
tive site connecting the catalytic H57 and D81 with residues R155, D168 and R123 [58,
68, 80, 94, 108]. Drug resistance mutations such as R155K and D168A are detrimental
because they (1) disrupt this electrostatic network reducing the proteins binding ability,
and (2) weaken inhibitor binding by destabilizing the interaction of the inhibitors P2 het-
erocyclic moiety. PIs with P2 moieties stacking against the electrostatic network, such as
vaniprevir, danoprevir and asunaprevir, experience decreases in inhibitor affinity when this
subsite is altered by mutations at R155 and D168. MK-5172, however, has a P2 moiety
that stacks against the catalytic residues, making the inhibitor less susceptible to the canon-
ical resistance mutations. This binding mode is beneficial for the pan-genotypic activity of
MK-5172, as the triad is invariant across genotypes. Our crystal structures show that the
stacking of the P2 quinoxaline in MK-5172 is maintained in linear and P1 − P3 macro-
cyclic analogs. Thus, P2 stacking against the catalytic triad is driven primarily by the
quinoxaline moiety and does not rely on the restraint exerted by the P2 − P4 macrocycle
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on the quinoxaline.
Macrocyclization increases inhibitor potency mostly by decreasing the entropic penalty
of binding by constraining the unbound inhibitors degrees of freedom and stabilizing the
inhibitor in a binding-competent conformation. Even without any stabilizing macrocycle,
the 5172 core, 5172-linear, has a Ki of 9.5 nM against WT protease (Table 3.4). This
low nanomolar inhibition constant relies on the highly favorable enthalpy of binding due
to the preservation of the parent compounds binding mode and efficient packing of the
quinoxaline moiety at the catalytic site. Without the macrocycle though, the linear analog
is likely highly flexible in the unbound state. The presence of a macrocycle prearranges
the inhibitor in binding competent conformation, favorably contributing to the entropy of
binding to further increase the potency to 1.96 nM in 5172-mcP1 − P3 and 0.14 nM in
MK-5172. In addition to contributing directly to inhibitor–protease hydrophobic interac-
tions, as is the case for the P2 − P4 macrocycle in MK-5172, the hydrophobic character of
the macrocycle can increase lipophilicity, and improve pharmacokinetic properties such as
cellular permeability and stability [104, 109, 110].
Protease inhibitors with a P2 − P4 macrocycle, such as MK-5172 and vaniprevir, are
susceptible to A156T mutation as the larger Thr sidechain can engage in a steric clash
with the macrocycle, displacing the inhibitor in the mutant complex structures [68]. In
the A156T–MK-5172 complex, the whole inhibitor including the P2 − P4 macrocycle is
pushed away from the active site due to A156T. Furthermore, the quinoxaline moiety
loses critical stacking interactions with H57 and D81. When the P2 − P4 macrocycle is
not present, in the A156T–5172-linear and A156T–5172-mcP1 − P3 complexes, the in-
hibitor can conformationally adapt to accommodate the A156T mutation. Thus, the 5172-
mcP1 − P3 analog has the advantage of macrocyclization while still maintaining critical
contacts with the catalytic residues.
Second generation protease inhibitors, such as MK-5172, have broader antiviral activity
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and higher barriers to resistance than first generation protease inhibitors [111]. However
even these inhibitors are not completely robust against drug resistance. In a recent clinical
trial [112], A156T variants with an additional V36M/V or I170V mutation were detected in
patients who failed therapy. Although the A156T viral variant is debilitated for replication
in vitro [113] coexisting compensatory mutations, as often seen in HIV-1 protease [114],
may recover viral fitness and lead to virological failure. Therefore, the development of
future NS3/4A PIs needs to encompass optimal strategies to best balance inhibitor potency
and barrier to resistance. The 5172-mcP1 − P3 analog provides opportunities for further
optimization of compounds with stable stacking interactions with the catalytic residues,
while staying within the substrate envelope. As the unique binding mode of MK-5172 is
preserved even without the P2 − P4 macrocycle, the removal of the macrocyclic linkage at
the P2 quinoxaline enables exploration of the chemical space to modify this group for an
even more potent inhibitor robust against resistance.
In rational drug design, the effect of macrocyclization on the entropy and enthalpy of
binding is not straightforward to predict, especially in the presence of resistance mutations.
While the macrocyclic constraint is beneficial for entropy, as we have demonstrated here
for MK-5172, the location of the macrocycle should be designed for optimal enthalpy as
well, to preserve the desired binding mode and ideally stay within the substrate envelope
[80,85]. The protrusion of the P2 − P4 macrocycle in MK-5172 outside the substrate enve-
lope effectively surrounding A156 causes vulnerability to mutations at this residue. In the
presence of A156T, while the rigidity brought about by the macrocycle is still beneficial
for entropy, the same rigidity is detrimental to enthalpy. Design of macrocycles should not
only fit within the substrate envelope but also consider both inhibitor rigidity and adaptabil-
ity to potential resistance mutations, to achieve optimal entropy–enthalpy balance required
for robustness to avoid susceptibility to resistant mutations.
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3.5 Materials and Methods
3.5.1 Protein Constructs
The HCV genotype 1a NS3/4A protease domain gene [68] was synthesized by Gen-
Script and cloned into the pET28a expression vector (Novagen). The highly soluble single-
chain construct consists of NS3/4A protease domain (residues 4–181) fused to a fragment
of the cofactor NS4A (residues 12–23) via an SD linkage. A similar protease construct
exhibited catalytic activity comparable to that of the authentic full-length protein [115].
All protease variants were generated using the QuikChange Site-Directed Mutagenesis Kit
from Stratagene.
3.5.2 Protein Expression and Purification
Protein expression and purification were carried out as previously described [85].
Briefly, transformed BL21(DE3) E. coli cells were grown at 37 ◦C and induced at an op-
tical density of 0.6 by adding 1 mM Isopropyl β-D-1-thiogalactopyranoside. Cells were
harvested after 5 hours of expression, pelleted, and frozen at -80 ◦C for storage. Cell pel-
lets were thawed, resuspended in 5 mL/g of resuspension buffer (50 mM phosphate buffer,
500 mM NaCl, 10% glycerol, 2 mM β-ME, pH 7.5) and lysed with a cell disruptor. The
soluble fraction was retained, applied to a nickel column (Qiagen), washed with resuspen-
sion buffer, and eluted with resuspension buffer supplemented with 200 mM imidazole.
The eluent was dialyzed overnight (MWCO 10 kD) to remove the imidazole, and the His-
tag was simultaneously removed with thrombin treatment. The nickel-purified protein was
then flash frozen and stored at -80 ◦C.
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3.5.3 Crystallization
The above-mentioned protein solution was thawed, concentrated to 3 mg/mL and
loaded on a HiLoad Superdex75 16/60 column equilibrated with gel filtration buffer, 25
mM 2-(N-Morpholino)ethanesulfonic acid (MES), 500 mM NaCl, 10% glycerol, 30 mM
zinc chloride, and 2 mM 1,4-Dithiothreitol, pH 6.5. The protease fractions were pooled and
concentrated to 20-25mg/mL with an Amicon Ultra-15 10 kD device (Millipore). The con-
centrated samples were incubated for 1 hour with 1-3 molar excess of inhibitor. Diffraction-
quality crystals were obtained by mixing equal volume of concentrated protein solution
with precipitant solution (20-26% PEG-3350, 0.1 M sodium MES buffer, 4% ammonium
sulfate, pH 6.5) in 24-well VDX hanging drop trays.
3.5.4 Data Collection and Structure Solution
X-ray diffraction data were collected either at Advanced Photon Source LS-CAT 21-
ID-F, or at our in-house Rigaku Saturn X-ray system. Diffraction intensities were indexed,
integrated and scaled using the program HKL2000 [116]. All structure solutions were
generated using molecular replacement with PHASER [89]. The B chain model of viral
substrate product 4A-4B (3M5M) [80] was used as the starting model for all structure
solutions. Initial refinement was carried out in the absence of modeled ligand, which was
subsequently built in during later stages of refinement. Subsequent crystallographic re-
finement was carried out within the Phenix program suite, with iterative rounds of TLS
or restrained refinement until convergence was achieved [117]. The protein crystals of
the A156T protease in complex with 5172-mcP1 − P3 grew as pseudo-merohedral twins.
X-Triage was used to determine the twin operator, -k,-h,-l thus refinement was carried out
using twin law= -k,-h,-l. This structure has 4 molecules in the asymmetric unit with the ac-
tive sites of molecules A and C superposed onto molecules B and D respectively. Molecule
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B was used in all of the analysis, as it possessed the lowest B factors representing the
most stable and consistent conformer. The final structures were evaluated with MolPro-
bity [118] prior to deposition in the Protein Data Bank. To limit the possibility of model
bias throughout the refinement process, 5% of the data were reserved for the free R-value
calculation [119]. Interactive model building and electron density viewing was carried out
using the program COOT [91].
3.5.5 Inhibitor Complex Analysis
Superpositions were performed in PyMOL [120] using the C-alpha atoms of the active
site protease residues 137139 and 154160. The A chain of WT–MK-5172 complex was
used as the reference structure for each alignment. Two conformations are observed in
the A156T–5172-linear structure, and the one with the lowest B factors within the P21
unit cell was used in the structural analysis. The van der Waals contact energies between
protease residues and inhibitors were computed using a simplified LennardJones potential
as described previously [121].
3.5.6 Molecular Dynamics Simulations
Molecular dynamics simulations were carried out, in triplicate, following previously
published protocols [94] using Desmond [122, 123] with the OPLS2005 force field [124,
125]. After equilibration, each trajectory was run for 100 ns at 300 ◦K and the coordinates
recorded every 5 ps. The dynamic inhibitor envelope was calculated using the van der
Waals volume of inhibitor conformers from the MD trajectories mapped onto the three-
dimensional grid placed on the binding site of the enzyme and normalized by the total
number of conformers to obtain a probability distribution, as detailed previously [94, 126].
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3.5.7 Isothermal Titration Calorimetry
ITC experiments were performed as previously described [127, 128]. Briefly, NS3/4A
protease was purified via gel filtration in 50 mM HEPES, 300 mM NaCl, 10% glycerol,
1 mM tris(2-carboxyethyl)phosphine at pH 7.4 and concentrated to 10–60 µM. Inhibitor
stock was prepared in 100% Dimethyl sulfoxide and diluted to working conditions in the
gel filtration buffer with final Dimethyl sulfoxide concentration not exceeding 3%. Exper-
iments were performed with a highly sensitive Microcal ITC200 (Malvern) at 25 ◦C with
the protein in the sample cell and inhibitor solution in the syringe. The data was analyzed
using Origin 7.0 and the change in enthalpy (∆H) and corresponding dissociation constant
(Kd) were determined via non-linear regression, with a one-binding site model. Due to
the potency of MK-5172, the inhibition constant from enzyme kinetics assay (Ki) of WT–
MK-5172 from our previous work [81] was used to calculate the Gibbs Free Energy (∆G),
as the Kd is too low to be reliably determined by ITC without a competing ligand [129]
which we were unable to successfully attain. All other ∆G calculations used ITC derived
Kd values.
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3.6 Supplemental Information
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B)
C)
A)
Figure 3.8: Changes in hydrogen bonding patterns across MD simulations.
Schematic representation of inter-molecular (blue dashed lines) and intra-molecular (red
dashed lines) hydrogen bonding fingerprints. (A) Hydrogen bonding interactions in
MK-5172, (B) 5172-mcP1 − P3 and (C) 5172-linear. The percentage of time the bond is
present during MD simulations are listed in the WT complexes (left), with the percent
changes greater than 5% shown in the A156T complexes (right).
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Protease–Inhibitor Replicon Ki Kd ∆H ∆T∆S ( kcal/mol) ∆G ( kcal/mol)
variant IC50 (nM) (nM) (nM) ( kcal/mol) Ki Kd Ki Kd
WT–MK-5172 0.29 0.14 1.5 -6.8 -6.6 N/A -13.4 N/A
(0.02) (0.4) (1)
WT–5172mcP1P3 0.26 1.96 2.2 -5.8 -6.0 -4.6 -11.8 -10.4
(0.13) (0.56) (0.7) (0.5) (0.2)
WT–5172-Linear 4.74 9.5 6.7 8.0 -2.9 3.1 -10.9 11.1
(0.75) (2.34) (0.58) (0.76) (0.2)
A156T–MK-5172 46.6 537 359.7 -4.1 -4.4 -4.5 -8.5 -8.8
(74) (0.09) (0.082) (0.44) (0.36)
A156T–5172mcP1P3 3.96 250 39.9 6.3 -2.7 3.9 -9 10.2
(29) (5) (1) (1.6) (0.54)
A156T–5172-linear 23.1 1708 154.3 6.9 -0.92 2.4 -7.8 9.3
(230) (4) (1) (1.2) (0.16)
Table 3.4: Binding thermodynamics of Mk-5172 and analog complexes
Actual dissociation constant (Kd) of WT–MK-5172 is below the sensitivity of ITC via
direct binding experiments. The inhibition constant from enzyme kinetics assay 1 (Ki)
was used as the Kd for Gibbs free energy (∆G) calculation of MK-5172. ∆G and T∆S
values are given with both Ki and Kd for comparison when appropriate. Values in
parentheses () represent the standard deviation.
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Figure 3.10: NS3/4A backbone dynamics during 100 ns MD simulations.
Cα root mean square fluctuations (RMSF) of MK-5172 (A), 5172-mcP1 − P3 (B) and
5172-linear (C). Regions in the protease displaying high C-alpha rmsf are numbered.
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Figure 3.11: Snapshots of NS3/4A inhibitor complexes during 100 ns MD simulations.
The Structural Alignments of NS3/4A complexes (white ribbons), the first (yellow) and
last (blue) frames of MD simulations, illustrate the various inhibitor conformations. In WT
complexes (B), both aligned frames superpose as judged by the stacking of the P2 prolines
(red circle). In A156T variant complexes (C), MK-5172 (bottom left) displays the highest
degree of inhibitor misalignment as its P2 proline rotates 90 degrees towards the S1′
binding site. 5172-mcP1 − P3 (bottom center) is able to maintain a similar conformation
as in the WT complex (top center). The P2 proline in A156T–5172-Linear (bottom right)
shifts 4 A˚ away from the active site and gets locked in an unfavorable conformation.
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Chapter IV
Elucidating the Molecular Basis for HCV Protease
Inhibitor Failure in Genotype 3
4.1 Abstract
Hepatitis C virus, affecting an estimated 150 million people worldwide, is the leading
cause of viral hepatitis, cirrhosis and hepatocellular carcinoma. The virus exhibits high
genetic diversity with over six genotypes and multiple subtypes. Genotypes 1 and 3, the
most prevalent viral species, have different geographic distributions. Recent advances in
direct-acting antivirals against Hepatitis C virus have led to the development of potent in-
hibitors of viral nonstructural proteins, including protease inhibitors several of which are
approved by regulatory agencies. Protease inhibitors are potent antivirals against genotype
1, but not genotype 3. Lack of structural information and difficulties developing a geno-
type 3 subreplicon model have limited our ability to understand this differential efficacy
of inhibitors. Here, we present structural and biophysical data elucidating the molecular
basis for genotype 3 NS3/4A escape from current protease inhibitors. We determined high-
resolution crystal structures of asunaprevir, danoprevir and vaniprevir in complex with a
genotype 1a-3a chimeric NS3/4A protease and compared these structures and their molec-
ular dynamics to those of native genotype 1a. We found that genotype 1 and 3 active sites
only differ by three amino acids (Arg/Thr123, Ile/leu132 and Asp/Gln168); and when these
polymorphisms are incorporated into a genotype 1 backbone, the resulting chimeric pro-
tease exhibits a similar response to inhibitors as the genotype 3 protease. This recapitula-
tion occurs via a disruption of the 155–168 electrostatic interaction, key for intermolecular
85
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dependence of quinoline and indoline based inhibitors.
4.2 Introduction
Hepatitis C virus (HCV) causes chronic liver infection that affects about 3% of the
global population and is the main cause of hepatitis, cirrhosis, and hepatocellular carci-
noma [69, 70, 130]. HCV is a highly evolved, highly diverse virus with six known geno-
types (GT) and multiple subtypes [2, 3]. The two most prevalent viral species, genotype
1 (GT-1) and 3 (GT-3) account for roughly 46% and 30% of the global infections respec-
tively [2, 4] and have a different geographic distribution. While GT-1 is most endemic in
Northern America and Europe, GT-3 is most prevalent in South Asia. The remaining GTs
4, 5 and 6 span the Middle East to Central Africa, South Africa, and Southeast Asia [2, 4].
Before the recent availability of direct-acting antivirals (DAAs), the standard of care
consisted of pegylated-interferonα (Peg-INF) and ribavirin (RBV), however, this treatment
had moderate to low rates of cure across genotypes and was poorly tolerated [96, 130].
Current therapeutic efforts aim to determine the best-in-class DAAs that target several viral
proteins including the viral entry protein, the NS3/4A protease, the NS5A and NS5B non
structural proteins [97] and host microRNAs [98] either individually or in combination.
Sofosbuvir (SOF), the HCV blockbuster drug, is a prodrug nucleotide analog targeting
the highly conserved palm region of the viral NS5B RNA dependent RNA polymerase
[97,131]. In a combination therapy with or without Peg-INF/RBV, more than 90% of GT-1
patients who received the SOF-based therapy experienced undetectable viremia, sustained
virological response (SVR24) for 24 weeks post treatment follow-up [132]. Thanks to
its high resistance barrier [133] and potency [131], SOF is progressively becoming the
backbone of the standard of care as it is currently approved for use in combination with
other DAAs, ledipasvir [134], simeprevir [112], and daclatasvir [135], resulting in greater
87
than 95% cure rates at 12 weeks post treatment follow-up, (SVR12) [71, 136].
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Figure 4.1: Schematic representation of NS3/4A protease inhibitors
The three broad classes of HCV PIs are shown: linear αketoamide covalent (top-black);
linear non covalent (second row-pink); and macrocyclic (P1-P3 and P2-P4 in red and blue
respectively.
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Four FDA-approved HCV inhibitors (telaprevir [31,32], boceprevir [35], simeprevir [39],
and most recently, paritaprevir [40]) target the NS3/4A protease (Fig. 4.1).
The NS3/4A protein is a bifunctional enzyme containing an N-terminal serine pro-
tease domain (amino acids 1-180) with the classic catalytic triad (S139, H57, D81) of the
chymotrypsin superfamily, and a C-terminal DExH/D-box helicase of superfamily II with
NTPase activity [99, 100, 102]. The NS3/4A protease is responsible for cleaving the vi-
ral polyprotein and host factors involved in the innate immune response, including TRIF
and mitochondrial antiviral signaling (MAVS) [26–28]. Serving as a two-pronged attack
on the virus by preventing viral maturation and restoring the immune response, targeting
the NS3/4A protease has historically been an industry priority. To date, NS3/4A protease
inhibitors (PIs) represent the largest class of DAAs. However, despite serving as the first
proof of principle for targeting an HCV viral protein [46, 137] and being extensively stud-
ied [111, 138–144], PIs suffer from a low genetic barrier to resistance [145] and lack of
cross-genotypic breadth. In fact, all PIs are ineffective against genotype 3 (GT-3) NS3/4A
protease.
GT-3 infected patients suffer from the lowest SVR rates. Only 60% GT-3 patients
treated with a Sofosbuvir monotherapy achieve SVR24 [146], whereas a combination ther-
apy of ribavirin and Sofosbuvir experienced SVR12 rates of 57% [147]. The recently FDA
approved combination of daclatasvir (a NS5A inhibitor) + sofosburvir results in roughly
96% SVR12 rates in GT-3 [148]; however, this therapy is only available in the US and the
standard of care for GT-3 patients outside of the U.S is still PEG-INF + RBV.
To elucidate the structural basis for differential efficacy of protease inhibitors in GT-3
relative to GT-1, we engineered a chimeric GT-1a3a (1a3a) protease to map the minimal
active site mutations necessary and sufficient for recapitulating GT-3 behavior. We then
determined high-resolution inhibitor co-crystal structures of GT-1a and 1a3a in complex
with asunaprevir (ASV), danoprevir (DAN) and vaniprevir (VAN). Through a detailed bio-
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physical, structural and dynamic analysis of the complexes, we find that, while GT-1 and
GT-3 share a 76% sequence identity, their active sites only differ by three polymorphism
R123T, I132L and D168Q. Incorporating the GT-3 polymorphism into the GT-1 protease
allows a recapitulation of GT-3 activity. The loss of inhibitor efficacy in the 1a3a and GT-3
proteases is a consequence of disrupted electrostatic interactions between amino acids 168
and 155, which is critical for potent binding of quinoline and isoindoline based PIs. We
reveal details of molecular and structural basis for the lack of PI efficacy against GT-3,
which are needed for design of pan-genotypic inhibitors.
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4.3 Results and Discussion
4.3.1 Protease inhibitors are significantly less potent in GT-3 than in
GT-1
To assess the efficacy of PIs in GT-1 and 3, we performed a comprehensive analysis
of enzyme inhibition constants (Ki values) for 7 PIs (telaprevir, boceprevir, asunaprevir,
danoprevir, vaniprevir, grazoprevir and MK-6325) representing the three general classes
of inhibitor (Fig. 4.2). Consistent with previous reports, the GT-3 NS3/4A protease is less
responsive to all PIs tested [51,149]. Among the first generation PIs, the reversible covalent
inhibitors telaprevir and boceprevir have a similar Ki against GT-1 (33 nM); however,
their potencies are differentially decreased in GT-3. While telaprevir’s potency decreases 8
fold (266 nM), boceprevirs Ki changes only by 2.2 fold (71 nM). Second wave inhibitors
(asunaprevir, danoprevir, and vaniprevir) have low to subnanomolar range (2.7, 1.0, 0.7 nM
respectively) potencies in GT-1, yet low to submicromolar Kis in GT-3. Relative the GT-1
the linear asunaprevir experiences a 975 fold change (FC) in Ki, while the macrocyclic
DAN and VAN experience a 878 and 533 FC respectively.
While the nature of the P2 moiety enhances potency, macrocyclization of PIs modulates
the extent of the potency enhancement [81], through improved entropic binding energet-
ics relative to their linear counterparts. The position of the macrocycle affects potency
enhancement as is evident when comparing the profiles of DAN and VAN, two inhibitors
containing the same isoindoline P2, but harboring different macrocyclic strategies. While
GT-1 WT protease is insensitive to the macrocyclization position, GT-3 favors the P2-P4
macrocycle. Of the panel, next generation PIs, grazoprevir (GRZ) and MK-6325, are the
most efficacious inhibitors against GT-1 (33 and 31 nM respectively). They are character-
ized by (1) a P2 quinoxaline and (2) a P2-P4 or P2-P4/P1-P3 macrocyclization for GRZ and
92
MK-6325 respectively. Here the improvement in inhibition is due to the synergistic effects
of the quinoxaline moiety, shown to favorably stack against the invariant catalytic residues,
and macrocyclization [68].
The differential efficacy of PIs across GT-1 and 3 is in agreement with the documented
failures of inhibitors against resistant variants caused by single or multi-amino acid mu-
tations [59, 80, 150]. Thus, a careful analysis of the protease amino acid sequence across
genotypes could provide insight into the molecular basis for PI failure in GT-3.
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Figure 4.2: Effects of active site point mutations on NS3/4A inhibition
Enzyme inhibition constants (Kis) for 7 PI were determined in four enzyme constructs:
WT–GT-1a (blue), WT–GT-3a (red), D168Q–GT-1a (orange),
R123T-I132L-D168Q-GT-1a (green).
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4.3.2 Of all genotypes, only GT-3 protease harbors active site poly-
morphisms
To analyze the diversity of NS3/4A across genotypes, sequences from the 6 genotypes
were aligned and percent identities were calculated. Across genotypes, the viral protease is
highly conserved with sequence identities and similarities ranging from 71-84% to 82-92%
respectively (Fig. 4.3). While the GT-3 NS3/4A has the second most divergent sequence
(76% identity vs. 71% in GT-2) relative to GT-1, all PIs are less potent against GT-3
protease than GT-2; with simeprevir, danoprevir, and vaniprevir more potent in GT-5 and
6 (both 82% identical to GT-1) than in GT-2. The various polymorphic sites are spatially
distributed throughout the protease in all six GTs (Fig. 4.4), with a distinct added feature
in GT-3.
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HCV.1a.M62321 100.0%
HCV.2b.D10988 71.1% 100 0%
HCV.3a.D17763 76.1% 70.6% 100 0%
HCV.4a.DQ418788 80 0% 73.3% 75.0% 100.0%
HCV.5a.AF064490 82 8% 74.4% 77.8% 80.0% 100 0%
HCV.6b.D84262 82 2% 73.3% 79.4% 81.7% 84.4% 100.0%
HCV.1a.M62321 HCV.2b.D10988 HCV.3a.D17763 HCV.4a.DQ418788 HCV.5a.AF064490 HCV.6b.D84262
HCV.1a.M62321 100.0%
HCV.2b.D10988 83 3% 100 0%
HCV.3a.D17763 87 8% 82.2% 100 0%
HCV.4a.DQ418788 90 0% 86.1% 86.7% 100.0%
HCV.5a.AF064490 93 3% 87.8% 87.8% 90.6% 100 0%
HCV.6b.D84262 92 2% 86.7% 90.6% 92.8% 92.2% 100.0%
HCV.1a.M62321 HCV.2b.D10988 HCV.3a.D17763 HCV.4a.DQ418788 HCV.5a.AF064490 HCV.6b.D84262
Reference protein HCV.1a.M62321 HCV.2b.D10988 HCV.3a.D17763 HCV.4a.DQ418788 HCV.5a.AF064490 HCV.6b.D84262
HCV.1a.M62321 1
HCV.2b.D10988 0.74 1
HCV.3a.D17763 0.78 0.74 1
HCV.4a.DQ418788 0.82 0.79 0.78 1
HCV.5a.AF064490 0.87 0.79 0.81 0.83 1
HCV.6b.D84262 0.84 0.77 0.81 0.83 0.86 1
 PERCENT IDENTITY MATRIX
PERCENT S MILARITY MATRIX
GLOBAL S MILARITY (BLOSUM62) RESULTS
Figure 4.3: HCV NS3/4A sequence simularity matrix
NS3/4A amino acid sequence simularity is shown for GT-1 through 6.
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Active site differences between GT-1 and GT-3 were mapped onto the protease structure
(Fig. 4.4B). The NS3/4A active site is highly conserved. Of the 36 residues in direct
contact with inhibitors (within 5 A˚ of the ligand), GT-3 differs in only 3 amino acids:
Thr123, Leu132 and Gln168 (Fig. 4.4C). While these changes represent an 8% divergence,
the nature of the change is functionally significant. The GT-1 positively charged Arg123
is substituted by a polar uncharged threonine in GT-3, while the negatively charged GT-1
Asp168 is mutated into a polar uncharged glutamine. These two changes effectively alter
the active site electrostatics and hydrogen bonding pattern. Amino acids 123 and 168 were
previously reported for their contribution to an active site salt bridge formation, inhibitor
binding, and resistance in the case of residue 168 [68, 94, 106]. Hence, polymorphisms
at the GT-3 protease active site may lead to electrostatic changes with implications for
inhibitor efficacy.
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Figure 4.4: Strcuturally mapping the HCV NS3/4A polymorphism
(A)Alignment of NS3/4A protease domain in GT 1 through 6 with consenesus and
weblogo displayed. Red stars identify amino acids located in the protease active site. (B)
Mapping of polymorphic differences between GT-1 and 3 active sites. GT-1 active site
residues involved in inhibitor-protease contacts (orange) are shown (left panel); GT-3
active site residues with differences relative to GT-1 shown (red).
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4.3.3 Polymorphisms at amino acids 123, 132, and 168 are responsible
for GT-3 specific decreased inhibitor potency.
To analyze the role of the Thr123, Leu132 and Gln168 polymorphisms on inhibitor ef-
ficacy, we engineered a single D168Q and triple R123T/I132L/D168Q (1a3a) mutant pro-
tease in the GT-1 background and characterized their enzyme inhibition profiles with the 7
PIs listed above (Fig. 4.2). In the linear covalent inhibitors telaprevir and boceprevir, the
D168Q single mutation does not significantly affect inhibitor potency relative to the GT-1
WT (1.2 and 0.7 FC respectively), likely due to a lack of an extended P2 moiety reliant
on interactions with the S2 subpocket. In contrast, this single mutation causes detrimental
effects on the non-covalent inhibitors. In ASV, DAN, VAN, and GRZ, the GT-1 D168Q
variant results in a 72, 30, 44 and 102 fold loss in potency relative to GT-1 WT. How-
ever, with only a 4-fold loss in potency, MK-6325 is able to accommodate the Asp to Gln
change and maintain a subnanomolar inhibition constant. The synergistic effects of MK-
6325’s bis-macrocycle and cyclopentyl P4 capping may underlie this sustained efficacy in
the presence of D168Q mutation (AppendixA). In the NS3/4A protease, amino acid 168 is
a multidrug resistance mutation hotspot with G/A/V/E/N/Y/K substitutions observed both
experimentally and clinically in GT-1 infected patients [59]. Understanding MK-6325’s
resistance profile and binding mode against D168 variants might provide insight into opti-
mizing PIs for better GT-3 targeting.
Introducing the R123T/I132L/D168Q triple mutation in GT-1 recapitulates the GT-3
inhibitor profile for most of the drugs in the panel. ASV, DAN, VAN and MK-6325 experi-
ence a three order of magnitude loss in potency relative to GT-1 WT, essentially mirroring
the observed loss of potency against GT-3. MK-6325 loses its advantage over D168Q
when I132L and R123T are present. Finally, the triple mutant has the same sensitivity as
the D168Q variant to BOC and GRZ, indicating this mutation is the main reason for the
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loss of potency against GT-3.
4.3.4 Crystal structures and molecular dynamics simulations of in-
hibitor complexes
To gain insights into the structural basis for GT-3 escape from PIs, we attempted to
structurally characterize native GT-3 protease. However, extensive crystallization efforts
were unsuccessful due to expression and purification challenges. Thus, we resorted to our
1a3a chimeric NS3/4A, which includes three key polymorphisms at the GT-3 active site and
fully recapitulates the inhibition profile. We determined high-resolution crystal structures
of ASV (5EQS), DAN (5EGR) and VAN (5ESB) in complex with 1a3a chimeric NS3/4A
protease (Table A1) and compared them to their corresponding GT-1 structures [85, 106].
To supplement this analysis, fully solvated 100 ns molecular dynamic (MD) simulations
were performed in triplicates for each of the complexes. The structures and simulations
permitted an in depth structural analysis of these complexes providing insights into the
molecular mechanisms which differentiate GT-3 activity.
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Table 4.1: Crystallographic Statistics of 1a3a in complex with asunaprevir, danoprevir and
vaniprevir
Asunaprevir (ASV) Danoprevir (DAN) Vaniprevir (VAN)
Complexes 1a/3a 1a/3a 1a/3a
PDB Code 5EQS 5EGR 5ESB
Resolution (A˚) 1.8 1.9 2.2
Space Group P212121 P212121 P212121
Molecules in AS 1 1 1
Cell Dimensions
a 39.1 54.9 55.1
b 60.3 58.4 58.3
c 79.6 59.9 59.9
β (◦) 90 90 90
Completeness (%) 92 92.8 94
Measured Reflections 69630 60292 33585
Unique Reflections 15339 14041 7436
Average I/(σ) 10.2 7.7 19.5
Redundency 4.4 4.3 4.5
R-merge (%) 9 9 6.2
RMSD in
Bonds (A˚) 0.015 0.012 0.042
Angles (◦) 1.6 1.3 1.8
Rfactor 19.3 16.5 18.2
Rfree 24.5 20 23.2
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4.3.5 Differences in GT-3 active site alter inhibitor packing
To analyze the details of inhibitor packing at the active site, van der Waals (vdW) in-
teraction energies between the inhibitor and protease residues in the crystal structures were
calculated (Fig. 4.5). In line with the inhibitor potency losses (Fig. 4.2), vdW contacts
are moderately lost in the 1a3a complexes relative to GT-1 (ASV: -44.4 vs. -45.3 kcal/mol;
DAN: -41.7 vs. -43.7 kcal/mol; and VAN: -41.1 vs. -41.5 kcal/mol). However these
changes in contacts are not sufficient to fully justify the extent of potency loss in GT-3.
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Figure 4.5: Surface representation of van der Waals potential energy of active site residues.
The vdW contact energy with the inhibitor mapped onto the protease surface in (A)
WT–GT-1 and (B) 1a3a chimera. The warmer (red) and cooler (blue) colors indicate more
and less contacts with the inhibitor, respectively.
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4.3.6 Disruption of the active site electrostatic network correlates with
inhibitor efficacy
In HCV protease, high-affinity ligand binding is characterized by formation of an elec-
trostatic network spanning residues D81, R155, D168, and R123 [68, 85]. Within this
network, R155–D168 interaction is particularly key for maintaining an electrostatic sur-
face that accommodates high-affinity ligand binding [106]. This interaction is present in
all GT-1 complex crystal structures (Fig. 4.6A), with both carbonyl oxygens of Asp168 ori-
ented towards Arg155’s N and Nη to form two hydrogen bonds (H-bonds) and Arg132’s
N oriented towards D168’s Oδ for one H-bond formation. However, in the 1a3a com-
plexes, the D168Q substitution results in simultaneous loss of the R155-Nη interaction and
maintenance of the 168-CO–155-N interaction (Fig. 4.6B).
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Figure 4.6: Mutation induced change in active site electrostatic interactions
Surface representation of protease-inhibitor complexes with Asunaprevir (left),
Danoprevir (center) and Vaniprevir (right) shown in orange sticks in the context of the
wild type GT-1 (A) and 1a3a chimeric protease (B). Catalytic residues and mutation sites
are highlighted in yellow and red respectively, while the observed electrostatic interaction
and hydrogen bonding (yellow dotted line) are shown in the inset.
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Rearrangements of this electrostatic interaction underlie the resistance mechanism of
many PIs, including asunaprevir and danoprevir, to the R155K multidrug resistant muta-
tion [68,106], where Asp168 side chain shifts towards Arg123 for electrostatic interaction.
With Gln168 only engaging in one H-bond with Arg155, the possibility of a rotation of
Gln168 to Arg123 for electrostatic interaction is feasible. Thus, to assess the stability
of the active site electrostatic interaction, we computed the average time the interactions
were observed during MD simulations (Table 4.2). The simulations revealed that, in all
three GT-1 complexes, both of D168s carbonyl oxygens were oriented towards Arg155’s
N and Nη over 93% of the simulation duration. In agreement with recent reports [107],
the Arg123–D168 interaction was only observed in the ASV and VAN complex roughly
30% of the time, suggesting that Arg123 might not be important for the formation of the
inhibitor binding surface.
With the loss of a terminal carboxyl group at amino acid 168, all three 1a3a complexes
experience weaker Gln168–Arg155 electrostatic interaction relative to their GT-1 counter-
parts. In ASV, this interaction is observed only during 47% of the simulation. This 52%
decrease relative to GT-1 is the most severe of the three complex structures and correlates
with ASVs weaker antiviral activity in GT-3. On the other hand, with DAN and VAN, the
168–155 interaction drops only by roughly 21% relative to their 1a counterparts suggesting
that the added rigidity of the ligand may help in maintaining the electrostatic interaction and
the electrostatics of the surface. Furthermore, there appears to be a macrocycle–location
dependent effect on the formation of the electrostatic surface. Comparing the three 1a3a
complexes, the Q168–R155 interaction is most persistent in DAN (78%) where the macro-
cycle is at the P1-P3 versus VAN (64%) and ASV (47%) representing respectively the
P2-P4 macrocyclic and linear inhibitors. The substitutions in GT-3 active site relative to
GT-1 do not significantly change protease–inhibitor intramolecular H-bonds, except for the
loss of at least one H-bond at the P1′ moiety for all three PIs. Overall, the molecular rear-
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rangements in ASV lead to the most changes in H-bond ranging from -10 to -61%, while
both DAN and VAN are better able to preserve their H-bonding interactions (Table 4.3).
Hence, the active site substitutions profoundly disrupt the active site electrostatic network
and consequently affect inhibitor binding and intermolecular H-bond signatures.
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4.3.7 Loss in enzyme–inhibitor atomic fluctuation correlations under-
lies inhibitor efficacy characteristics.
To assess the overall consequences of the active site substitutions on protease–inhibitor
dynamics, we computed the root square mean fluctuations (RMSF) of both inhibitor and
protease Cα atoms during the MD simulations. The 1a3a triple mutation had little influence
on the backbone Cα RMSF values relative to the GT-1, suggesting that the overall protein
dynamics remained intact (Fig. 4.9). However, the inhibitors atomic fluctuations changed
both depending on the inhibitor and when bound to the chimeric protein relative to GT-
1. While the inhibitor backbone appears relatively rigid, the P2 moieties sample different
degrees of mobility (Fig. 4.7).
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Figure 4.7: Root square mean fluctuations of inhibitor atoms during MD simulations
Atomic RMSF of asunaprevir (orange), danoprevir (blue) and vaniprevir (magenta) in
complex with WT–GT-1 (solid lines) and 1a3a (dashed lines) during 100 ns MD
simulation are shown.
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In ASV, the isoquinoline undergoes the highest RMSF fluctuations of the complexes
(up to 4 A˚ RMSF) regardless of the protein construct. DAN’s isoindoline is rigid com-
pared to ASV (1 A˚ RMSF) but becomes more dynamic in the 1a3a complex (2 A˚ RMSF).
VAN, with its P2-P4 linked isoindoline, has the most rigid P2 of the three inhibitors and
undergoes no change in fluctuations due to the 1a3a mutations. Intriguingly, the differ-
ences in inhibitor P2 atomic fluctuations is inversely correlated with intermolecular vdW
contacts and binding potency (Fig, 4.2 and 4.5A). ASV’s isoquinoline is highly dynamic
in GT-1, yet, among the three inhibitors, it makes the least contacts with the protease S2
residues resulting in the weakest-binding inhibitor. The isoindoline in both DAN and VAN
display very low fluctuations, but make strong contacts with the S2 residues, producing
tighter-binding drugs. Hence, there is an interdependent relationship between inhibitor P2
flexibility, protease-inhibitor contacts and potency.
In principle, tight binding inhibitors are characterized by strong intermolecular interac-
tions, which persist over the dynamics of the enzyme [94]. To draw a stronger link between
the interdependence of the electrostatic interaction and the binding modes of inhibitor P2
isoquinoline and isoindoline, we determined cross-correlation coefficients of atomic fluc-
tuations between protease active site residues and inhibitor atoms. During the MD simu-
lations, atom pairs either fluctuate in the same direction (positive correlation, COi.j = 1),
opposite direction (negative correlation, COi.j = −1) or have random movements with
respect to one other (no correlation, COi.j = 0).
In the 1a complexes, ASV and VAN display strong positive (COi.j > 0.6) correla-
tions, specifically with respect to protease residues 132 through 157 and including 168 (Fig.
4.10), whereas DAN has both positive and negative correlations with respect to residues 132
through 168 and 41 through 43 respectively. In addition to the conserved R155–D168 in-
teraction revealed by conserved H-bond interactions, the cross correlation analysis showed
high cooperativity between the P2 moieties of ASV and DAN with R155–D168 residues.
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VAN’s isoindoline has positive correlations with R155 but not with D168. It is possible
that the D168 aids in stabilizing the R155’s conformation for parallel stacking with the
heterocyclic rings.
In the 1a3a complexes, the cross-correlations exhibit significant alterations ranging
from partial losses to complete disruption compared to GT-1. In ASV, the P4-P3 moieties
experience complete loss of correlations with eight residues, 132 through 154 (Fig.4.8),
constituting the oxyanion hole, S1 pocket and the 310-helix located between β strands C2
and D2. This disruption in correlations at the S1 subpocket is in agreement with the ob-
served loss in P1′ intermolecular interactions in this inhibitor. Similar to ASV, DAN suffers
complete disruptions in correlations with respect to residues 132 through 138 (Fig. 4.11).
While protease–P4-P3 moiety correlations are somewhat maintained in the 1a3a com-
plexes, the intermolecular cooperativity relative to the inhibitor P2 moieties of ASV and
DAN is completely abolished due to the mutations (Fig. 4.8B, 4.11B) but slightly main-
tained for VAN (Fig. 4.12B).
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4.3.8 Conclusions
HCV therapeutic efforts have greatly benefited from structure based drug design (SBDD),
specifically protease inhibitors. The elucidation of the structural mechanism for substrate
binding, coupled with rational medicinal chemistry efforts, has spawned the current land-
scape of PIs with subnanomolar potency and remarkable antiviral activity. Sadly, this ac-
tivity is genotype dependent and new more effective therapies are needed for GT-3 in-
fected patients. The same SBDD efforts that have facilitated these advancements are hin-
dered by the lack of GT-3 protease structural information and robust design tools. In this
study, we reveal the major contributors to PI failure in GT-3, and demonstrate that three
active site polymorphisms, R123T-I132L-D168Q, are responsible for efficacy loss of cur-
rent PIs against GT-3. Our crystal structures and dynamic analysis indicate that the active
site electrostatics, which we have reported previously to be key for tight ligand binding
[68, 106, 107], are disrupted by GT-3 active site polymorphism.
The molecular mechanisms underlying loss of PI efficacy against GT-3 relative to GT-
1 is reminiscent of drug resistance due to active site mutations in GT-1 protease [68, 107],
understanding drug resistance can serve as a template for understanding inhibitor efficacy in
GT-3 protease. The ability of single active site mutations to confer multidrug resistance has
been extensively studied, specifically in the context of D168 resistance associated variants.
These mutations unfavorably alter or completely disrupt the electrostatic network required
for ligand binding. Inhibitors that retain potency against D168 variants of GT-1 protease
may be better inhibitors for GT-3 protease, and the chimeric 1a3a protease that we have
constructed here can be used to test such designed inhibitors for GT-3 activity in both
structural studies and potentially replicon assays.
In viruses like HCV, where 1012 new virions are produced daily, it is estimated that
every possible nonsense mutation is introduced in the viral genome on a daily basis [62].
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Consequently, a heterogeneous viral population exists in every patient. However, outside
of the native GT-3 context, neither the single D168Q nor the simultaneous presence of the
triple R123T/I132L/D168Q mutations has been reported. The absence of these mutations in
GT-1 suggests other secondary GT-3 polymorphisms outside the active site may be required
for maintaining protease fitness. In the context of GT-3, the R123T and D168Q mutations
disrupt the R123-D168-R155 electrostatic network to an only Q168–R155 interaction.
A thorough understanding ligand-receptor interactions is key for a successful drug dis-
covery project. For instance, an appreciation for the molecular basis for drug resistance
in HIV-1 protease was not possible until a complete understanding of the atomic basis for
substrate recognition and inhibitor binding was established. The resulting findings, known
as the substrate envelope hypothesis (SEH), demonstrated that (1) active site amino acids
prone to resistance associated variants correspond to sites where an inhibitor protrudes out-
side of the consensus substrate vdW volume [151]. (2) When used as an added constraint
in drug development, the SEH has led to the design robust inhibitors with enhanced resis-
tance barriers and improved antiviral activity [152]. SEH was successfully implemented
to design HIV PIs more robust against resistance in SBDD, and was fundamental in our
understanding of the structural basis for HCV drug resistance [80,85]. In addition to SEH,
the study of atomic cross-correlations we present here for the 1a3a chimera could greatly
enhance PI design against GT-3. For instance, inhibitor moieties could be first modeled in
1a3a and tested for their ability to maintain or increase correlations relative to GT-1. As
both the P4-P3 and P2 moieties of ASV, DAN, and VAN were shown to lose correlations
in the chimeric complex, SAR studies to identify moieties with stronger cross correlations
could yield more robust inhibitors. This hypothesis is supported by a recent report detailing
a P4 capping SAR in a faldaprevir derivative [153].
In conclusion, we present the alterations in the active site electrostatics as the molecular
mechanism underlying loss of PI efficacy against HCV GT-3, and a chimeric 1a3a protease
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amenable for structural studies for the study and future development of more robust GT-
3 NS3/4A inhibitors. By mapping the major amino acids responsible for the differential
activity of PIs across GT-1 and GT-3, our chimera enables understanding the lack of po-
tency of PIs against GT-3 protease, allows for a direct comparison of ligand binding modes
against the extensive repertoire of GT-1 inhibitor complexes, and serves as an added tool in
the computational drug discovery toolkit. The commonality between mechanisms underly-
ing drug resistance due to D168 active site mutations in GT-1 and loss of potency against
GT-3 promises the possibility of designing inhibitors robust against both GT-1 mutations
and GT-3 polymorphisms. Revealing molecular mechanisms of how polymorphisms al-
ter inhibitor binding across genotypes should not be limited to HCV or other Flaviviruses,
but be applied to other rapidly evolving diseases where viral heterogeneity alters inhibitor
efficacy across genotypes.
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4.4 Materials and Methods
4.4.1 Protein Constructs
The HCV genotype 1a NS3/4A protease domain gene [68] was synthesized by Gen-
Script and cloned into the pET28a expression vector (Novagen). The highly soluble single-
chain construct consists of NS3/4A protease domain (residues 4–181) fused to a fragment
of the cofactor NS4A (residues 12–23) via an SD linkage. A similar protease construct
exhibited catalytic activity comparable to that of the authentic full-length protein [115].
All protease variants were generated using the QuikChange Site-Directed Mutagenesis Kit
from Stratagene.
4.4.2 Protein Expression and Purification
Protein expression and purification were carried out as previously described [68]. Briefly,
transformed BL21(DE3) E. coli cells were grown at 37 ◦C and induced at an optical density
of 0.6 by adding 1 mM IPTG. Cells were harvested after 5 hours of expression, pelleted,
and frozen at -80 ◦C for storage. Cell pellets were thawed, resuspended in 5 mL/g of resus-
pension buffer (50 mM phosphate buffer, 500 mM NaCl, 10% glycerol, 2 mM β-ME, pH
7.5) and lysed with a cell disruptor. The soluble fraction was retained, applied to a nickel
column (Qiagen), washed with resuspension buffer, and eluted with resuspension buffer
supplemented with 200 mM imidazole. The eluent was dialyzed overnight (MWCO 10
kD) to remove the imidazole, and the His-tag was simultaneously removed with thrombin
treatment. The nickel-purified protein was then flash frozen and stored at -80 ◦C.
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4.4.3 Crystallization
The above-mentioned protein solution was thawed, concentrated to 3 mg/mL and loaded
on a HiLoad Superdex75 16/60 column equilibrated with gel filtration buffer, 25 mM 2-(N-
Morpholino)ethanesulfonic (MES), 500 mM NaCl, 10% glycerol, 30 mM zinc chloride,
and 2 mM 1,4-dithiothreitol, pH 6.5. The protease fractions were pooled and concentrated
to 20–25 mg/mL with an Amicon Ultra-15 10 kD device (Millipore). The concentrated
samples were incubated for 1 hour with 1–3 molar excess of inhibitor. Diffraction-quality
crystals were obtained overnight by mixing equal volume of concentrated protein solution
with precipitant solution (20–26% PEG-3350, 0.1 M sodium MES buffer, 4% ammonium
sulfate, pH 6.5) in 24-well VDX hanging drop trays.
4.4.4 Data Collection and Structure Solution
X-ray diffraction data were collected on an in-house Rigaku X-ray system with a Sat-
urn 944 CCD detector. Diffraction intensities were indexed, integrated and scaled using the
program HKL2000 [116]. All structure solutions were generated using molecular replace-
ment with PHASER [89]. The B chain model of viral substrate product 4A-4B (PDB ID:
3M5M) [80] was used as the starting model for all structure solutions. Initial refinement
was carried out in the absence of modeled ligand, which was subsequently built in during
later stages of refinement. Subsequent crystallographic refinement was carried out within
the Phenix program suite, with iterative rounds of TLS or restrained refinement until con-
vergence was achieved [117]. 1a3a–VAN complex was refined using the CCP4 program
suite [154]. The final structures were evaluated with MolProbity [118] prior to deposition
in the Protein Data Bank. To limit the possibility of model bias throughout the refinement
process, 5% of the data were reserved for the free R-value calculation [119]. Interactive
model building and electron density viewing was carried out using the program COOT [91].
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4.4.5 Enzyme Inhibition Assays
All enzyme inhibition assays were performed in nonbinding surface 96-well black half-
area plates (Corning) in a reaction volume of 60 µL. The NS3/4A protease (2 nM) was
preincubated with increasing concentration of drugs in 50 mM Tris, 2.5% glycerol, 0.1%
OβG, 5 mM Tris(2-carboxyethyl)phosphine, 1% Dimethyl sulfoxide, pH 7.5 for an hour.
The reaction was initiated by the rapid injection of 5 µL of HCV NS3/4A protease sub-
strate, Ac-DE-Dap(QXL-520)-EE-Abu-ψ-[COO]AS-C(5-FAMsp)- NH2 (Anaspec), to a
final concentration of 200 nM and kinetically monitored using a Perkin-Elmer EnVision
plate reader (excitation at 485 nm; emission at 530 nm). At least four independent data
sets were collected for each inhibitor with each protease construct. Each inhibitor titration
included at least 12 inhibitor concentration points, which were globally fit to the Morrison
equation to obtain the Ki value [81].
4.4.6 Structural Analysis
Superpositions were performed in PyMOL [122] Cα atoms of the active site protease
residues 137–139 and 154–160. The A chain of WT–asunaprevir complex was used as the
reference structure for each alignment. Hydrogen bonding analysis was carried out in Mae-
stro, Schrodinger suite, with bond distance and donor-acceptor angles cutoff of 3.5 A˚ and
120◦, respectively. VAN der Waals contact energies between protease–inhibitor residues
were computed using a simplified Lennard–Jones potential, as described previously [121].
4.4.7 Molecular Dynamics Simulations
Molecular dynamics simulations were carried out in triplicate, following previously
published protocols [94] using Desmond [122] with the OPLS2005 force field [124] [125].
After equilibration, each trajectory was run for 100 ns at 300 ◦K and the coordinates recorded
118
every 5 ps. The percentage of time a hydrogen bond existed between the protease and an
inhibitor was calculated using VMD [155]. A hydrogen bond was defined by a distance
between the donor and acceptor of less than 3.5 A˚ and a hydrogen-donor-acceptor angle
of less than 30◦. Only the hydrogen bonds that existed more than 20% of the time were
considered in the analyses. Salt bridges were defined as an interaction between a side-chain
oxygen atom of Asp or Glu within 4.0 A˚ of a nitrogen atom of Arg or Lys [156].
4.4.8 Atomic Fluctuation Dynamics
The normalized cross-correlations of residue pairs were defined as:
CO(i.j) =
〈−−→∆Ri · −−→∆Rj〉
(〈∆Ri2〉〈∆Rj2〉)1/2
where Ri is the fluctuation in the position vector R of site i and Rj is the fluctuation in the
position vector R of site j. The brackets represent time averages over recorded snapshots.
The cross-correlations vary in the range [-1, 1], with the lower and upper limits indicating
fully anticorrelated and correlated atomic fluctuations, respectively. COi,j = 0 reflects
uncorrelated atomic fluctuations.
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Asunaprevir Danoprevir Vaniprevir
WT 1a3a WT 1a3a WT 1a3a
SER1139-Main-N P1’ SO1 3.1(48.1%) 2.9(89.4%) 2.7(<20%) 2.7(<20%) 2.7(86.6%) 2.8(<20%)
SER139 H P1’ SO1 1.9(<20%) >3.5(<20%) >3.5(<20%) >3.5(<20%) >3.5(<20%) >3.5(<20%)
SER1139-Side-Oγ P1’ SO1 2.1(17.4%) >3.5(38.7%) >3.5(<20%) 2.0(19.8%) >3.5(92.6%) 2.1(20.2%)
GLY1137-Main-N P1’ SO2 2.2(70.1%) 2.2(81.6%) 2.3(83.2%) 2.3(85.2%) 2.1(84.6%) 2.2(88.2%)
HIP1057-Side-N2 P1’ NH 2.1(<20%) 2.0(62.1%) 2.1(34.9%) 2.2(59.3%) 2.0(61.3%) 2.1(58.1%)
GLY1137-Main-N P1 CO 2.0(<20%) 2.1(<20%) 2.0(<20%) 2.1(<20%) 2.3(<20%) 2.2(<20%)
SER1138-Main-N P1 CO 2.9(<20%) 3.0(<20%) 2.7(<20%) 2.5(<20%) 2.8(<20%) 2.6(<20%)
SER1139-Side-Oγ P1 CO 2.6(<20%) 2.8(<20%) 2.6(<20%) 2.5(<20%) 2.7(<20%) 2.5(<20%)
ARG1155-Main-O P1 NH 1.9(57.5%) 2.0(84.4%) 1.9(66.7%) 2.0(84.4%) 2.0(92.6%) 1.9(83.6%)
ALA1157-Main-O P3 NH 1.9(43.3%) 1.9(41.9%) 1.9(82.0%) 1.9(79.2%) 2.0(88.2%) 2.0(82.0%)
ALA1157-Main-N P3 CO 1.9(75.1%) 1.9(60.7%) 1.9(85.4%) 2.0(80.4%) 1.9(83.0%) 1.9(83.0%)
Table 4.2: 1a3a Intermolecular H-bonding network of protease inhibitor complexes.
Hydrogen bond network observed in both crystal structures (distance in A˚) and their
averaged persistence during 100ns simulations (percent time).
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Asunaprevir Danoprevir Vaniprevir
WT 1a3a WT 1a3a WT 1a3a
TYR56-Main-N ASP81-Main-O 2.1(80.4%) 2.0(18.0%) 2.2(81.6%) >3.5(50.1%) 2.2(80.4%) >3.5(23.0%)
TYR56-Main-N ASP81-Side-Oδ2 >3.5(<20%) >3.5(<20%) >3.5(<20%) >3.5(<20%) >3.5(<20%) >3.5(<20%)
HIS57-Main-N ASP81-Side-Oδ 1.8(72.5%) 1.9(93.8%) 1.9(72.1%) 1.8(82.6%) 1.9(72.5%) 1.8(85.1%)
HIS57-Side-Nδ1 ASP81-Side-Oδ 1.6(96.8%) 1.6(89.2%) 1.6(98.4%) 1.6(96.4%) 1.6(96.8%) 1.8(97.0%)
ARG123-Side-N ASP168-Side-Oδ1 2.7(<20%) >3.5(<20%) 2.4(<20%) >3.5(<20%) 1.9(<20%) >3.5(<20%)
ARG123-Side-NH2 ASP168-Side-Oδ1 >3.5(31.3%) >3.5(<20%) >3.5(<20%) >3.5(<20%) 3.4(31.3%) >3.5(<20%)
LYS136-Main-N ILE132-Main-O 2.3(28.1%) 2.0(25.8%) 2.2(<20%) 2.3(<20%) 2.1(28.1%) 2.5(<20%)
SER138-Side-Oγ LYS136-Main-O >3.5(10.0%) >3.5(<20%) >3.5(33.5%) >3.5(21.2%) >3.5(<20%) >3.5(<20%)
SER138-Side-Oγ GLY137-Main-O >3.5(<20%) >3.5(<20%) >3.5(<20%) >3.5(<20%) >3.5(<20%) >3.5(<20%)
GLY140-Main-N PHE154-Main-O 1.8(90.0%) 1.9(92.2%) 1.9(85.4%) 1.8(80.4%) 1.9(90.0%) 1.9(88.4%)
GLY141-Main-N SER138-Main-O >3.5(<20%) 2.2(<20%) 2.1(<20%) 2.2(19.2%) 2.1(<20%) 2.2(<20%)
PHE154-Main-N GLY141-Main-O 1.8(96.0%) 1.8(96.2%) 1.8(96.0%) 1.8(94.2%) 1.8(96.0%) 1.7(94.8%)
ARG155-Main-N ASP168-Main-O 1.9(81.8%) 1.9(67.7%) 2.0(76.1%) 1.9(60.1%) 1.9(81.8%) 1.9(69.9%)
ARG155-Side-N ASP168-Side-Oδ2 1.6(99.2%) >3.5(25.0%) 1.7(99.0%) >3.5(<20%) 1.9(99.2%) >3.5(<20%)
ARG155-Side-N GLN168-Side-O1 >3.5(<20%) 1.8(47.7%) >3.5(<20%) 2.1(78.2%) >3.5(<20%) 1.7(63.7%)
ARG155-Side-NH1 GLN168-Side-O1 >3.5(<20%) >3.5(<20%) >3.5(<20%) 2.6(<20%) >3.5(<20%) >3.5(<20%)
ARG155-Side-NH1 ASP168-Side-Oδ1 2.3(94.2%) >3.5(<20%) 2.4(54.3%) >3.5(<20%) >3.5(94.2%) >3.5(<20%)
ARG155-Side-NH1 ASP168-Side-Oδ2 >3.5(<20%) >3.5(<20%) >3.5(39.3%) >3.5(<20%) 1.8(<20%) >3.5(<20%)
ARG155-Side-NH2 LYS80-Main-O 1.9(76.1%) 1.7(46.1%) 2.0(81.6%) 2.2(78.0%) 2.0(76.1%) 2.1(67.7%)
ALA156-Main-N ASP168-Main-O 2.1(50.1%) 2.1(86.6%) 2.1(71.5%) 2.2(90.2%) 2.1(50.1%) 1.9(88.4%)
VAL158-Main-N ALA166-Main-O 1.9(63.3%) 1.9(60.1%) 1.9(82.8%) 1.8(75.3%) 1.9(63.3%) 2.2(69.9%)
LYS165-Main-N VAL158-Main-O 2.6(<20%) 2.2(19.0%) 2.3(46.9%) 2.0(<20%) 2.3(<20%) 2.4(<20%)
ASP168-Main-N ALA156-Main-O 1.8(71.3%) 1.8(77.1%) 1.8(85.2%) 1.6(70.1%) 1.8(71.3%) 1.6(66.1%)
Table 4.3: 1a3a Intramolecular hydrogen bonding network of protease inhibitor complexes
Hydrogen bond network observed in both crystal structures (distance in A˚) and their
averaged persistence during 100ns simulations (percent time).
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Figure 4.9: Root square mean fluctuations of protease C atoms during MD simulations.
Atomic RMSF of asunaprevir (orange), danoprevir (blue) and vaniprevir (magenta) in
complex with WT–GT-1 (solid lines) and 1a3a (dashed lines) during 100 ns MD
simulation are shown.
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Figure 4.10: Effect of 1a3a mutations on intrinsic Protease–inhibitor dynamic cooperativ-
ity.
Atomic fluctuation cross-correlation matrix of active site residues from GT-1 (A) and 1a3a
(B) in complex with asunaprevir (left), danoprevir (center) and vaniprevir (right).
Correlation coefficients are represented using a red–blue color scale where positive and
negative correlations are represented by red and blue shades respectively.



Chapter V
Discussion
5.1 Rational Drug Design
The history of HCV antiviral development is a success story. The available HCV pro-
tease inhibitor (PI) discovery literature chronicles medicinal chemistry efforts and structure
activity relationship (SAR) studies focused on identifying lead compounds with high antivi-
ral activity and a favorable pharmacokinetic profile against GT-1 protease [46,66,92,157].
While these goals were met, the rapid rise of drug resistance variants severely undermined
these achievements. Sadly, incorporation of resistance associated variants (RAVs) into
the lead candidate optimization process did not occur until the discovery of grazoprevir
(GRZ) [79] in 2012, 8 years after the discovery of the first PI [48] and the first report of
drug resistance in PIs [158]. Consequently, protease inhibitors suffer severely from drug
resistance, and any treatment based on them must be supplemented with a different class
of antivirals [112, 150, 159] to achieve high sustained virological response (SVR) rates.
Resistance is a serious problem that all drugs targeting rapidly evolving diseases face.
A thorough characterization of the genomic and structural basis for resistance is critical for
robust antiviral design and should be a priority in the current rational drug design paradigm.
However, a full understanding of resistance cannot be established until elucidation of the
targets substrate recognition has been completed [152, 160]. However, once this critical
phase is finalized, a clean picture of the structural determinants for viral escape can be
painted while incorporating inhibitor binding information.
In 2010, when I joined the Schiffer laboratory, our group had just established the molec-
ular basis for substrate recognition in HCV NS3/4A protease, effectively defining the HCV
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substrate envelope [80]. My contributions to the advancement of our field start with an
extensive structural characterization of inhibitor binding modes and how they change with
respect to resistance variants [68, 106] (Fig. 5.1).
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Figure 5.1: Structural characterization of HCV NS3/4A protease–inhibitor complexes.
Surface representation of the HCV NS3/4A protease (white) in complex with the various
inhibitor (orange sticks) studied in this thesis. Active site amino acid prone to resistance
are highlighted in magenta (R155), red (A156) and green (D168); catalytic residues and
Cys159 are shown in yellow.
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5.2 Picking the right medicinal chemistry strategy
In HCV PI development, while structure based drug design (SBDD) has greatly in-
fluenced design efforts, strong and creative medicinal chemistry programs were the true
driving force for the therapeutic advancements. Unfortunately, these two methods have not
always worked hand in hand. Each novel discovery served as a building block for future
generations of inhibitors. For example, the P2 quinoline derivative was first synthesized in
BILN-2061 and modified versions were synthesized in asunaprevir, sovaprevir, GS-9451,
faldaprevir, and simeprevir. The main handicap with this approach is low PI diversification
and possible generation of a class of ineffective compounds. When we evaluated the effect
of P2 identity on inhibitor potency by comparing three compounds, which only differed
by their P2 moiety (quinoline, isoquinoline and quinoxaline), we demonstrated that the P2
quinoline had the worst antiviral profile of the three moieties with respect to drug resistance
variants and the quinoxaline performed the best [81] (Fig. 5.2).
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By designing quinoline based compounds with no significant alterations, various re-
search groups have essentially created a subclass of PIs with the same drug resistance pro-
file. Going forward, rational drug design of PIs must incorporate SBDD to create inhibitors
that are designed to perform well against drug resistant variants. Our findings propose the
use of a quinoxaline moiety at P2 as a starting point for future PI development. Two main
findings prompt this suggestion: (1) the quinoxaline favors a unique intermolecular interac-
tion with catalytic residues, forming the foundation for GRZ’s improved resistance barrier
relative to other PIs; and (2) our crystallographic studies have shown potential chemical
space for P2 extension and enhancement. The former rationale is supported by the pres-
ence of ordered water molecules at two sites in the structures of GRZ in complex with the
protease: near the P2 6-position methoxy group on one hand and the 1-position nitrogen
atom of the quinoxaline ring system on the other. One commonly used SBDD strategy is to
extend an inhibitor towards the location of ordered water molecules with a functional group,
which preserves water mediated intermolecular hydrogen bonding interactions [161, 162].
The recent discovery of MK-2748 illustrates this principle [163] and supports my recom-
mendation. In that work, a SAR study was used to explore the favorability of a hydrogen
bond acceptor external to GRZ’s quinoxaline ring at the N-1 position. The study demon-
strated that use of a carbonyl group at this N-1 position led to improved antiviral activity
against known multi-drug resistance variants (MDRs) and GT-3 regardless of the P2 hete-
rocyclic identity.
Future PI developments efforts should explore the use of a 3-chloro-6-methoxyquinoxaline
moiety at P2 with SAR at positions 1 and 6 toward the ordered waters.
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5.3 Macrocyclization and thermodynamic optimization
Macrocyclic HCV PIs have significantly improved potency and resistance profiles rel-
ative to their linear counterparts [81]. A factor contributing to these enhancements is the
stabilization of the inhibitor in a binding competent conformation while allowing for suffi-
cient flexibility to accommodate resistance mutations [164]. In GRZ, the P2−P4 is flexible
enough to accommodate amino acid changes at R155 and D168, but not A156. Conversely,
the P1 − P3 macrocycle can accommodate all three amino acid changes because it is lo-
cated away from the RAVs hotspot in a buried subpocket. While the choice between the
two strategies might seem simple, picking the right macrocyclization strategy, one that will
lead to a highly potent compound with suitable absorption, distribution, metabolism, and
excretion (or ADME) profile, is not a trivial task as overall antiviral activity is influenced
by the synergistic effect of all of the inhibitor moieties.
The thermodynamic forces (enthalpy and entropy) governing ligand binding affinity
can be experimentally determined via isothermal titration calorimetry (ITC). In HIV, a thor-
ough characterization of the thermodynamic signature of protease inhibitors revealed that
binding of the newer and more potent HIV PIs is predominantly enthalpically driven, favor-
ing intermolecular hydrogen bonding and van der Waals contacts over entropically driven
forces (hydrophobic interactions, desolvation, and rigidity) [165]. Knowledge of a lig-
and’s thermodynamic footprints can serve as a platform for potency enhancement through
enthalpic or entropic optimization [166]. My thermodynamic characterization of GRZ’s
acyclic and macrocyclic analogues showed that the macrocyclic compounds were signifi-
cantly more entropically driven than their acyclic counterparts. Additional thermodynamic
characterization of HCV PIs needs to occur before we can know the feasibility of a ther-
modynamic optimization. Nonetheless, an enthalpic optimization can serve as a guide for
SAR studies.
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Taken together, my recommendation for future drug design efforts is to include the P1−
P3 macrocycle strategy coupled with the aforementioned 3-chloro-6-methoxyquinoxaline
moiety at P2. A SAR study guided by enthalpy optimization could yield robust inhibitors.
5.4 Targeting genotype 3 protease
A recent study, aimed at developing a pan-genotypic PI, demonstrated that enhancing
the potency and pharmacokinetic profile of GRZ relative to GT-3 could be achieved [167].
In this study, the GRZ’s quinoxaline based P2 − P4 moieties were substituted for a quino-
line based P2 − P4. The resulting quinoline was extended at position 4 toward a con-
served Asp at position 79 at the interface with the helicase domain. The hypothesis behind
this strategy was that a charge complementarity to Asp79 could improve potency. The
use of electrostatic complementarity as a basis for inhibitor development is an established
method [168] with many successful applications, such as with human des-Gla-coagulation
factor Xa [169]. The lead compound of the pan-genotypic inhibitor study contained a bi-
cyclic piperidine-ether at the 4-position of the quinoline based P2−P4, a methylcyclopropyl
sulfonamide at P1′ , and a cyclohexyl P3 moiety. Relative to GRZ, these changes increased
antiviral activity against GT-3 by 50 fold (0.26 vs. 13.0 nM EC50) and improved pharma-
cokinetics in rats (0.7 vs. 1.2 AUC, uM/h). An additional significant discovery from this
study is that the lead inhibitor, compound 37, is less susceptible to the A156T MDR variant
than GRZ (0.42 vs. 5.3 nM). We have shown that P2 − P4 macrocyclic compounds are
susceptible to the A156T mutation because the threonine clashes with the macrocycle, re-
sulting in unfavorable binding [68]. The improved potency in compound 37 would suggest
that the macrocycle in this specific instance has sufficient flexibility to accommodate muta-
tions at 156. Future studies should attempt to structurally characterize this novel quinoline
based P2 − P4 strategy.
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An alternative pan-genotypic strategy worth exploring is the use of a bis-macrocycle
and P4 cyclopentyl capping similar to MK-6325 [163]. This compound is identical to GRZ
with the exception of a cyclopentyl P4, a methylcyclopropyl sulfonamide at P1′ , and the
addition of a P1 − P3 macrocycle. Relative to GRZ, these modifications in MK-6325 re-
sulted in a two-fold and four-fold improvement in potency against GT-3 (0.26 vs. 0.7 nM
IC50), and GT-1 WT (0.005 vs. 0.02 nM) respectively. With this antiviral activity profile,
MK-6325 has reached a PI milestone, being the first single digit picomolar inhibitor in
GT-1 and outcompeting GRZ with respect to major MDR variants R155K (0.07 vs. 0.013
nM), A156T (5.3 vs. 0.42 nM) and D168Y (0.14 vs. 0.036 nM) [163, 167]. My struc-
tural characterization of MK-6325 (appendix A) elucidated the mechanism by which the
potency improvement occurs. While the cyclopentyl P4 allows the P2 − P4 macrocycle
sufficient flexibility to accommodate amino acid changes at residue 156, unlike the cyclo-
propyl ring in GRZ, the P1−P3 macrocycle behaves like an electronic resistor and reduces
the susceptibility against D168 RAVs. As mutations at D168 confer resistance to GRZ in
the clinic [170] and a D168Q polymorphism accounts for a major part of the loss in po-
tency of PIs relative to GT-3, strategies that improve antiviral activity against D168 RAV
could serve a dual purpose of increasing the overall resistance barrier and augmenting pan-
genotypic breadth. The 1a3a chimera cross-correlation analysis of atomic fluctuations that
I describe in chapter IV could provide valuable insights for a rapid and streamlined in silico
evaluation of candidate moieties.
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5.5 Implications for other evolving diseases
Outside of HCV in the Flaviviridae family, flaviviruses such as Dengue virus (DENV)
and West Nile Virus (WNV) infect millions of people and cause widespread morbidity and
mortality [171, 172] Like HCV, DENV and WNV are positive strand RNA viruses com-
posed of similar structural and non structural machinery [173, 174]. Their viral NS2B/3
protein is a serine protease, and like the HCV NS3/4A, it is responsible for polyprotein
processing and viral maturation [174]. To date, no approved DAA against either DENV or
WNV exists, underscoring the urgency for robust drug development. The DENV and WNV
proteases are attractive drug targets and can benefit from the strategies developed for HCV
PIs. Several reports describe the binding modes of small peptides to the DENV NS2B/3
protease [172,175,176] and an examination of DENV serotype-3 protease in complex with
the Bz-nKRR-H peptide shows the C terminal Arginine 4.1 A˚ away form the N-terminal
benzoyl group (Fig. 5.3). This proximity within the S1 − S4 subpockets favors the incor-
poration of a macrocyclic linkage between the P1 − P4 inhibitor moieties. Recently, the
first nanomolar DENV-WNV peptide inhibitor was described (12 nM IC50), however, it
lacks in vivo efficacy (3.4 µM EC50) [177]. Incorporating macrocycles in inhibitor design
should not only improve potency but also enhance pharmacokinetic and pharmacodynamic
properties [104, 110]. As the inhibitors become more advanced and are less peptide-like,
design efforts should have a strong drug resistance analysis and prevention focus. Lessons
learned from both HIV and HCV proteases could accelerate antiviral discovery efforts.
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5.6 Concluding remarks
When this thesis research started, HCV infected over 180 million individuals worldwide
and had no approved direct acting antiviral. Thanks to relentless efforts, close to a dozen
therapeutic options currently exist for patients and their doctors. These therapies, reliant on
combinations of NS5B polymerase, NS3/4A protease and/or NS5A inhibitors, have raised
SVR above 95% while reducing the time of therapy to 12 weeks instead of the initial 48.
Despite these significant improvements in disease treatment, efforts to develop novel robust
antivirals must not slow down, as the efficacy of DAAs and access to cure rates are greatly
diminished in genotype 3 infected patients. It is my sincere hope my work will inspire
future scientists in their efforts to develop robust inhibitors.

Appendix A
Structural Characterization of MK-6325, a
Bis-Macrocyclic Next-Generation Pangenotypic
HCV NS3/4A inhibitor
1.1 Preface
Chemically, MK-6325 and GRZ share three key features the same peptidomimetic
backbone, P2 methoxy-quinoxaline, and lastly, P2 − P4 macrocycle. However, MK-6325
is different from GRZ in that it carries a methylcyclopropyl sulfonamide at P1′ , a larger P4
capping and has P1 − P3 macrocycle. the MK-6325 is not only is first NS3/4A PI to use a
bis-macrocyclic strategy but its also the first PI to achieve a single digit picomolar antiviral
activity in GT-1.
To gain insight into the atomic basis for MK-6325’s enhanced antiviral activity, I solved
its structure in complex with WT and A156T and compared those with previously solved
MK-5172, 5172-mcP1−P3 structure. All experiments and data collection have been com-
pleted and a manuscript for submission as a communication is in preparation. The follow-
ing figures highlight my findings:
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Complexes/crystal WT–MK-6325 A156T–MK-6325
Resolution (A˚) 1.7 1.85
Space Group P212121 P212121
Molecules in AS 1 1
Cell Dimensions
a 34.12 36.59
b 58.7 58.12
c 81.88 79.32
β (◦) 90 90
Completeness (%) 99.7 99.8
Measured Reflections 243253 60489
Unique Reflections 46302 15038
Average I/σ 16.8 20.6
Redundency 5.4 4
R-merge (%) 5.9 3.7
RMSD in
Bonds (A˚) 0.008 0.008
Angles (◦) 1.614 1.64
Rfactor 17.74 18.75
Rfree 22.14 21.93
Table A1: Crystallographic statistics of MK-6325 in complex with Wild type and A156T
drug resistant variant.
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MK-5172 MK-6325 MK-2748
GENOTYPE Variant IC50 (nM) Fold Increase IC50 (nM) Fold Increase IC50 (nM) Fold Increase
1A WT 0.015 1.0 0.032 1.0 0.038 1.0
1A (R155K) 0.084 5.5 0.086 2.7 0.10 2.7
1B WT 0.0067 1.0 0.017 1.000 0.024 1.0
1B (A156S) 0.051 7.6 0.072 4.4 0.060 2.5
1B (A156T) 4.3 642 0.72 44 3.7 151
1B (A156V) 6.0 892 1.2 70 3.6 149
1B (D168A) 0.35 52 0.086 5.2 0.093 3.8
1B (D168E) 0.038 5.6 0.048 2.9 0.043 1.8
1B (D168V) 0.14 21 0.089 5.4 0.057 2.3
1B (D168Y) 0.15 23 0.088 5.3 0.11 4.5
1B (R155K) 0.030 4.6 0.030 1.8 0.059 2.4
3A WT 0.98 0.57 2.2
Table A2: Antiviral activity of GRZ, MK-6325 and MK-2748

144
Figure A3: MK-6325’s van der Waals contact energy by inhibitor moiety
(A) Relative van der Waals interaction of MK-6325 (green), MK-5172 (red) and
5172-mcP1 − P3 (blue) across P1′ − P4 moieties are shown with dark and light shades
representing the WT and A156T variant respectively. (B) changes in vdW contact
potentials the A156T relative to WT.
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Figure A4: dynamic effects of the bis-macrocyclization on inhibitor’s flexibility
The dynamic inhibitor envelope when bound to (A) WT and (B) A156T protease. Red and
blue indicate less and more flexible regions of the inhibitor, respectively.
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1.2 Summary of findings
• P4 cyclopentyl ring engages in more hydrophobic interactions that the cyclopentyl
capping potentially underlying potency enhancements in D168 resistance associated
variants.
• P4 cyclopentyl ring increase the inhibitor’s dynamic flexibility, allowing it to accom-
modate the A156T mutation.
Appendix B
Structural Characterization of RFS-256
2.1 Preface
This project was a collaboration between the Schiffer laboratory at UMass Medical
School and Schinazi Laboratory at RFS Pharma.
The goal was to investigate the structural binding mode of RFS-256, a linear analog of
Danoprevir but with trifluoromethyl at P4.
2.2 Methods and Results
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Complexes WT-RFS-256
Resolution (A˚) 2
Space Group P21
Molecules in AU 2
Cell Dimensions
a 55.2
b 58.5
c 60.1
β (◦) 90
Completeness (%) 98
Measured Reflections 99451
Unique Reflections 2389
Average I/σ 11.8
Redundency 4.1
R-sym (%) 5
RMSD in
Bonds (A˚) 0.013
Angles (◦) 1.7
Rfactor 14.5
Rfree 19.9
Table B1: Crystallographic statistics of RFS-256.
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2.2.1 Conserved active site packing
Figure B1: Surface representation of RFS-256 and Danoprevir
Surface representation of WT-NS3/4A in complex with (A) Danoprevir (magenta) and (B)
RFS-256 (orange) with key active site residues highlighted: catalytic triad (H57, D81 and
S139) in yellow and sites prone to multidrug resistance mutations R155, D168 and A156
shown in blue, green and red, respectively.
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Figure B2: Structural overlay of RFS-256 and Danoprevir
Cα structural superposition of WT–Danoprevir (magenta) and WT–RFS-256 (orange)
reveals a 0.2 A˚ root mean square deviation (RMSD).
151
2.2.2 RFS-256 is characterized by similar vdW contact landscape as
Danoprevir
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Key findings:
1. Catalytic residues D81 and S139 in WT-RFS-256 lose contacts relative to WT-Danoprevir;
2. Danoprevir associated resistance sites, 155 and 168 gain contacts in WT-RFS-256;
3. D168, R123 and V158 exhibit altered vdW potential due to RFS-256’s P4 capping
group.
Appendix C
Secondary Contribution 1: Molecular Basis for
Drug Resistance in HCV
3.1 Secondary Contribution
Author contributions: DS expressed, purified, crystallized various protease–inhibitor
complexes in this study. Additionally, DS participated in data collection, analysis as well
as manuscript preparation.
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over the past two decades. Both boceprevir and telaprevir are
linear ketoamide compounds that form a reversible, covalent bond
with the catalytic serine of NS3/4A protease. Several non-covalent
xprotease inhibitors have also advanced into human clinical trials;
these inhibitors include both linear (BMS-650032 [22], BI 201335
[23]) and macrocyclic compounds, containing either a P1 P3
(danoprevir [24], TMC435 [25]) or a P2 P4 (vaniprevir [26], MK-
5172 [27]) macrocycle (Figure 1).
The NS3/4A protease inhibitors rapidly reduce HCV RNA
titers when administered as monotherapy [17,28 31] and
substantially improve SVR rates when given in combination with
Peg-IFN and RBV [6 10,32 34]. However, the high rate of HCV
replication and poor fidelity of HCV’s RNA-dependent RNA
polymerase lead to heterogeneous virus populations in infected
patients [35,36]. These viral quasispecies exist at low levels in
untreated patients, and resistant populations emerge under the
selective pressure of direct-acting antiviral agents [36 38]. In the
majority of patients undergoing protease inhibitor therapy,
resistance develops rapidly due to overlapping but distinct sets of
NS3/4A mutations [37]. In patients with genotype 1a, the R155K
mutation causes resistance against nearly all inhibitors, but rarely
occurs in genotype 1b patients [29,30,32,37 42]. Instead, distinct
resistance mutations arise in genotype 1b patients depending on
the class of protease inhibitor used; A156 mutates in response to
treatment with linear ketoamide protease inhibitors [39 41], while
macrocyclic inhibitors more commonly select for D168A and
R155K variants [29,30,32,42]. Mutations at V36, T54, and
V36+A155 are also associated with resistance to ketoamide
inhibitors [39 41]. Variations in the patterns of resistant mutations
arise from the complex interplay between genotype, replication
rates, mutation rates, and the resulting effect of mutations on viral
fitness and drug potency. Clearly, despite the benefits of
combination therapy in improving SVR rates, the emergence of
resistance challenges the long-term efficacy of NS3/4A protease
inhibitors.
Most primary drug-resistance mutations in NS3/4A protease
occur around the active site in regions where drugs protrude from
the substrate binding space, defined as the substrate envelope,
because these changes can preferentially disrupt drug binding
with minimal effect on substrate binding and viral fitness [43].
The protease inhibitors danoprevir, TMC435, and boceprevir
protrude from the substrate envelope in regions that correlate
with known sites of resistance mutations. Notably, the large P2
moieties of danoprevir and TMC435 bind in the S2 subsite and
extensively interact with residues R155, D168, and A156 [43],
which mutate to confer multi-drug resistance [37,38,44]. These
and other inhibitors with large P2 moieties derive much of their
potency from binding in the S2 subsite [45], but how molecular
changes at these residues selectively weaken inhibitor binding
without compromising the binding of viral substrates is not clear.
Elucidating the underlying molecular mechanisms of NS3/4A
protease inhibitor resistance is therefore essential for developing
new drugs that are less susceptible to resistance.
How single-site mutations at residues R155, A156 and D168
confer resistance against most protease inhibitors has not been
elucidated in atomic detail. In this study, we report that four
chemically representative protease inhibitors telaprevir, dano-
previr, vaniprevir and MK-5172 exhibit distinct susceptibilities
to the protease variants R155K, A156T and D168A (Table 1).
Sixteen high-resolution crystal structures of inhibitors in complex-
with the wild-type protease and three drug resistant variants
reveal the molecular basis underlying the unique resistance
profiles of these inhibitors (Table 2). The P2 quinoxaline moiety
of MK-5172 stacks against the protease catalytic triad in a novel
conformation, explaining its retained potency against R155K and
D168A. The flexible P2 isoindoline moiety of danoprevir
containing a P1 P3 macrocycle packs against the mutated
surfaces of A156T and D168A variants, explaining its relatively
higher activity against both protease variants. However, the
isoindoline moiety in vaniprevir is constrained due to the P2 P4
macrocycle, resulting in significantly lower activity against all
three variants. Thus, incorporating either quinoxaline or flexible
substituents at the P2 proline confers clear advantages. Taken
together, these data highlight potential strategies for designing
novel drugs that retain potency against a broader spectrum of
resistant viral variants.
Results
Drug susceptibility assays
Drug activities were determined for telaprevir, danoprevir,
vaniprevir and MK-5172 against wild-type genotype 1a HCV
and resistant variants R155K, D168A, and A156T using viral
replicon-based inhibition assays. The antiviral activities against
the resistant variants trended with changes in binding affinities
measured in enzyme inhibition assays (Table 1). Against wild-type
protease, macrocyclic inhibitors danoprevir, vaniprevir and MK-
5172 exhibited antiviral potencies in the sub nM range
(IC50 0.24, 0.34 and 0.11 nM, respectively), while telaprevir
potency was significantly lower (IC50 1030 nM), consistent with
previous reports [46,47]. Relative to the wild type, R155K caused
large reductions in potency for danoprevir and vaniprevir, but
MK-5172 remained highly active (R155K IC50 0.55 nM).
Telaprevir potency was slightly better against D168A relative to
the wild type, while danoprevir, vaniprevir and MK-5172 lost
100- to 1000-fold potency against D168A. However, both
danoprevir and MK-5172 still were significantly more potent
than telaprevir against D168A. Among the macrocyclic drugs,
danoprevir and MK-5172 retained higher activities against
D168A (D168A IC50 48 nM and 13 nM, respectively) relative
to vaniprevir (D168A IC50.400 nM). Danoprevir also retained
significantly higher potency against A156T (A156T
IC50 5.7 nM), while the other three drugs incurred large-fold
Author Summary
Hepatitis C virus (HCV) infects over 170 million people
worldwide and is the leading cause of chronic liver diseases,
including cirrhosis, liver failure, and liver cancer. New classes
of directly acting antiviral agents that target various HCV
enzymes are being developed. Two such drugs that target
the essential HCV NS3/4A protease are approved by the
FDA and several others are at various stages of clinical
development. These drugs, when used in combination with
pegylated interferon and ribavirin, significantly improve
treatment outcomes. However HCV evolves very quickly
and drug resistance develops against directly acting antivi
ral agents. Thus, despite the therapeutic success of NS3/4A
protease inhibitors, their long term effectiveness is chal
lenged by drug resistance. Our study explains in atomic
detail how and why drug resistance occurs for four
chemically representative protease inhibitors –telaprevir,
danoprevir, vaniprevir and MK 5172. Potentially with this
knowledge, new drugs could be developed that are less
susceptible to drug resistance. More generally, understand
ing the underlying mechanisms by which drug resistance
occurs can be incorporated in drug development to many
quickly evolving diseases.
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losses in potency. Notably, MK-5172, though active against the
other two variants, lost significant potency against A156T
(A156T IC50 108 nM). Thus, the four drugs exhibited varied
susceptibilities to protease inhibitor-resistant viral variants
R155K, D168A and A156T.
Structure determination and analyses
To elucidate the underlying mechanism by which chemically
diverse inhibitors bind to the wild-type protease and drug-resistant
variants, crystal structures were determined for 16 inhibitor-
protease complexes. These complexes include wild-type protease
and resistant variants R155K, D168A and A156T each bound to
telaprevir, danoprevir, vaniprevir and MK-5172, with resolutions
ranging from 1.10 2.50 A˚ (Table 2); S139A protease variants were
used except for telaprevir, which requires covalent bond formation
with the serine 139 for efficient binding. These high-resolution
data sets afforded very detailed structural interpretations of drug-
protease binding.
The binding conformations of telaprevir, danoprevir, vaniprevir
and MK-5172 to the wild-type protease are shown in Figure 2 and
Figure S1. In all complexes, inhibitors formed three common
hydrogen bonds with the protease backbone (Table S1): (1) the P1
amide nitrogen with the carbonyl oxygen of R155, (2) the P3
carbonyl oxygen with the amide nitrogen of A157, and (3) the P3
amide nitrogen with the carbonyl oxygen of A157 (Figures 3A
6A). The P5 amide nitrogen of telaprevir formed an additional
hydrogen bond with the carbonyl oxygen of S159. In the telaprevir
complex, the catalytic serine (S139) was covalently bound to the C-
a carbon of the ketoamide warhead. The ketoamide oxygen sat in
the oxyanion hole and interacted with the backbone amide
nitrogens of protease residues 137 139, while the Ne nitrogen of
H57 hydrogen bonded with the keto oxygen. The acylsulfonamide
groups of danoprevir, vaniprevir and MK-5172 were also
positioned in the oxyanion hole, hydrogen bonding with the same
set of backbone amide nitrogens, as observed previously for the
TMC435 and danoprevir structures [43,45]. Meanwhile the Ne
nitrogen of H57 interacted with the sulfonamide nitrogen in these
complexes, suggesting that the Ne atoms were deprotonated.
Thus, many of these classes of inhibitors overlap in several key
interactions with the protease.
In wild-type complexes involving macrocyclic inhibitors, R155
adopted a conformation distinct from those observed in telaprevir
and substrate complexes to allow binding of the extended P2
moieties in the S2 subsite. This R155 conformation is stabilized by
hydrogen bond interactions involving D168 and D80. The
conformation has also been observed for protease in complex
with TMC435 and danoprevir, where large P2 moieties of
inhibitors are positioned over the guanidine side chain, making
extensive cation-p stacking interactions [43,45]. Vaniprevir, with
the P2 isoindoline moiety, bound in a conformation similar to
danoprevir, making favorable cation-p stacking interactions with
R155, despite the P2 P4 macrocycle. In contrast, MK5172
adopted a novel conformation with the ether-linked P2 quinox-
aline moiety not interacting extensively with R155 and D168, but
stacking instead against H57 and D81 of the catalytic triad
(Figure 2). Thus, the P2 moieties of these three macrocycles pack
in a variety of conformations around the active site.
To characterize binding patterns of the drugs relative to natural
substrates, the wild-type drug complexes were analyzed with
respect to the substrate envelope, the consensus binding volume of
the substrates [43] (Figures 3A 6A). Inhibitors are generally more
vulnerable to resistance where they protrude beyond the substrate
envelope and contact residues less essential for substrate recogni-
tion and turnover. All four drugs protruded from the substrate
envelope in the protease S2 subsite near residues R155, A156 and
D168, which individually mutate to confer multi-drug resistance
[37,38,44]. Telaprevir, with the small P2 cyclopentylproline
moiety, made fewer van der Waals contacts with R155, A156
and D168 relative to danoprevir and vaniprevir, which contain the
carbamate-linked P2 isoindoline moieties that protruded from the
substrate envelope and made extensive van der Waals contacts
with these residues (Figures 3A 5A). Danoprevir’s isoindoline
moiety bound in two conformations in the wild-type complex, but
adopted a single conformation in mutant complexes. Notably MK-
5172, with an ether-linked P2 quinoxaline moiety, while protrud-
ing from the substrate envelope, stacked against the catalytic triad,
avoiding direct van der Waals contact with R155 and D168
(Figure 6A). Thus, although each of these drugs protruded from
the substrate envelope at the S2 subsite, each formed unique
interactions with R155, A156 and D168. Mutations at these
residues therefore differentially affected drug binding and potency,
resulting in a distinct resistance profile for each inhibitor.
Telaprevir resistance
Telaprevir lost potency against R155K compared to the wild-
type protease, although the crystal structures of both complexes
were very similar maintaining the covalent bond between the
ketoamide moiety and the catalytic serine (Figure 3B). R155K,
however, lost interactions with D168, thereby disrupting the
electrostatic network spanning R123, D168, R155 and D81,
which is important for telaprevir binding. These rearrangements
modulated the charge landscape along the protease surface,
disrupting interactions with the adjacent P2 cyclopentylproline
and P4 cyclohexylalanine moieties of telaprevir, consistent with
previous modeling studies [48]. Interestingly, telaprevir showed
better potency against the D168A variant than the wild-type; the
crystal structure revealed that the P2 moiety bent considerably and
packed closer against the D168A variant. The inhibitor shifted by
approximately 0.5 A˚ relative the position in the wild-type
complex, resulting in increased interactions with both R155 and
A156 (Figures 3C, 7A). However, the A156T mutation resulted in
a steric clash with telaprevir’s P2 moiety, causing the inhibitor to
shift significantly; the inhibitor P2 moiety moved away from R155,
losing van der Waals interactions with the protease (Figures 3D,
7A). Notably, in the A156T-telaprevir complex the covalent bond
between the ketoamide warhead and the catalytic serine was
extended to greater than 2 A˚, suggesting a reduced capacity for
covalent modification, consistent with the large loss in potency
against A156T (Table 1). Thus, while telaprevir’s flexibility allows
adaptation to D168A, it cannot accommodate the disruption by
R155K or A156T. The relatively weak binding affinity of
telaprevir to wild-type protease results in a potentially narrow
range by which resistant mutations can be tolerated.
Danoprevir and vaniprevir resistance
For both danoprevir and vaniprevir, the R155K mutation
disrupted the favorable cation-p stacking interactions with the P2
isoindoline moieties (Figure 4B), causing significant reductions in
drug potencies (Table 1). The D168A mutation also disrupted
stacking of the P2 moieties with R155, by disrupting the
electrostatic network and therefore the position of R155 for
optimal cation-p stacking. In danoprevir, the P2 isoindoline
moiety shifted in response to R155K and D168A mutations,
making extensive interactions with the catalytic D81 (Figure 7B).
For vaniprevir, the rigidity of the P2 P4 macrocycle prevented
similar compensatory changes (Figure 5C). Thus, D168A caused
losses in danoprevir and vaniprevir potency by disrupting cation-p
stacking. However, the flexibility of the P2 moiety of danoprevir
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compensates somewhat for this loss, explaining danoprevir’s
greater potency against the D168A variant relative to vaniprevir
(Table 1).
The A156T mutation sterically impinges on the binding of
danoprevir and vaniprevir. In both complexes with A156T, the P2
moieties shifted toward the catalytic triad and lost cation-p
stacking interactions with R155. However, the flexibility of the P2
moiety of danoprevir permitted a larger shift, which allowed for
more compensatory packing against the A156T variant protease
surface (Figure 4D). In contrast, the P2 P4 macrocycle of
vaniprevir restrained the P2 moiety and inhibitor’s ability to
accommodate this steric burden, more strongly compromising the
activity of vaniprevir. Thus, the flexible P2 moiety of danoprevir
allowed it to retain significant potency against A156T variants
compared to vaniprevir.
MK 5172 resistance
Unlike in the danoprevir and vaniprevir complexes with wild
type, in the MK-5172-wild-type complex the P2 quinoxaline
moiety did not stack on R155 and interacted less with D168 and
the electrostatic network involving these residues. Thus, the single-
site mutations R155K and D168A only caused very subtle changes
in the MK-5172 binding conformations (Figures 6B and 6C). This
subtle effect is reflected in the small loss of potency against the
R155K variant (Table 1); however, MK-5172 exhibited 100-fold
lower potency against the D168A variant, likely due to less
extensive interactions with D81 and K136 relative to wild-type
and R155K (Figure 7). A156T, the worst of the resistance
mutations for MK-5172A, sterically clashed with the P2 P4
macrocycle and caused a large shift in the binding position away
from the catalytic triad relative to its wild-type structure
(Figure 6D). This altered binding of MK-5172 resulted in fewer
van der Waals contacts with D81 and R155, and is likely
responsible for 1000-fold lower potency against the A156T
variant. Overall, analysis of the four crystal structures explains
MK-5172’s significantly retained potency against R155K and
D168A as well as its loss of potency against the A156T variant due
to the rigidity of the macrocycle (Table 1).
Discussion
Despite the exciting therapeutic success of NS3/4A protease
inhibitors, their long-term effectiveness is challenged by drug
resistance. In this study we explain the molecular basis of this drug
resistance against four NS3/4A protease inhibitors, telaprevir,
danoprevir, vaniprevir and MK-5172, representing the major
Figure 2. The binding conformations of telaprevir, danoprevir, vaniprevir and MK-5172. Surface representations of the wild-type
protease in complex with (A) telaprevir, (B) danoprevir, (C) vaniprevir, and (D) MK-5172. The catalytic triad is shown in yellow and the R155, A156 and
D168 side chains are highlighted in light-blue, pale-green and red, respectively.
doi:10.1371/journal.ppat.1002832.g002
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chemical classes of these inhibitors. Our detailed analysis of 16
high-resolution crystal structures explains the loss of inhibitor
potency in the face of resistance mutations. This research supports
our substrate envelope model, which stipulates that inhibitors are
vulnerable to resistance where they contact protease residues
beyond the substrate-binding region and therefore are not essential
for substrate binding [43]. These sites can mutate with minimal
effect on protease function and viral fitness. Indeed, most
resistance mutations occur in regions where drugs protrude from
the substrate envelope, as these changes selectively disrupt drug
binding with minimal effect on substrate proteolysis.
The most potent of the NS3/4A protease inhibitors is MK-
5172. We report here, for the first time, a novel binding
conformation for MK-5172 in which the P2 quinoxaline moiety
binds far from the S2 subsite and instead stacks against the
catalytic residues H57 and D81. Unlike other inhibitors, MK5172
does not directly interact with R155 and D168, which mutate to
confer multi-drug resistance. This unique binding mode of MK-
5172 explains its significantly greater potency against R155K and
D168A variants compared to other inhibitors. MK-5172 has a
unique barrier to resistance, as neither catalytic residue (H57 or
D81) can tolerate mutation. This binding conformation of MK-
Figure 3. Stereo view of the telaprevir complexes. (A) Telaprevir bound to the wild-type protease with the substrate envelope in blue. Intra-
and inter-molecular hydrogen bond interactions are marked as red and grey dashed lines. Telaprevir is also shown bound to the drug-resistant
variants (B) R155K, (C) D168A and (D) A156T with the transparent coordinates representing the wild-type structure to better highlight the molecular
changes of each mutation. In all cases, catalytic residues are depicted in yellow, the P2 subsite in pink, and the drug molecules in orange.
doi:10.1371/journal.ppat.1002832.g003
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5172, combined with its picomolar binding affinity [27] (Table 2),
will likely allow it to retain potency against a broad array of
resistant viral variants and genotypes.
We define the structural basis for differential drug activities
against the resistant variants R155K, D168A, and A156T for four
major chemical classes of NS3/4A protease inhibitors. Telaprevir
has reduced potency against R155K due to loss of van der Waals
contacts but exhibits better potency against D168A as it allows
tighter packing in the S2 subsite. R155K and D168A mutations
confer danoprevir and vaniprevir resistance by disrupting favor-
able cation-p stacking interactions with R155. Interestingly, while
both drugs lose considerable potency against R155K, danoprevir
retains higher activity against D168A. This difference is likely due
to the flexible P2 isoindoline moiety of danoprevir, which lacks
P2 P4 cyclization and repacks against the D168A variant.
Similarly, vaniprevir and MK-5172 exhibit significantly lower
potency against the A156T variant due to direct steric clashes,
while danoprevir partially accommodates this steric burden by
repacking against the mutated surface. Thus, the flexibility of
danoprevir’s P2 isoindoline moiety allows it to retain activity
Figure 4. Stereo view of the danoprevir complexes. (A) Danoprevir bound to the wild-type protease with the substrate envelope in blue. Intra-
and inter-molecular hydrogen bond interactions are marked as red and grey dashed lines. Danoprevir is also shown bound to the drug-resistant
variants (B) R155K, (C) D168A and (D) A156T with the transparent coordinates representing the wild-type structure to better highlight the molecular
changes of each mutation. In all cases, catalytic residues are depicted in yellow, the P2 subsite in pink, and the drug molecules in orange.
doi:10.1371/journal.ppat.1002832.g004
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against two of the three major drug-resistant variants. Structural
analysis of the 16 protease-inhibitor complexes defines the role of
all three major drug-resistance mutations.
Our results also provide predictions of drug activities against
other HCV genotypes and resistant strains. Interestingly, NS3/4A
residues around the protease active site, including R155, A156,
and D168 are highly conserved except genotype 3 viruses which
contain the residues Q168 and T123, instead of D168 and R123
found in other genotypes (Figure S2). We predict that the terminal
amide group of Q168 will be unable to stabilize R155 for stacking
against the P2 moieties of danoprevir and vaniprevir, but may
interact with T123 instead. Thus, we expect that danoprevir and
vaniprevir will exhibit reduced potencies against genotype 3
viruses, while MK-5172 will remain fully active. Indeed,
danoprevir and vaniprevir were recently shown to have reduced
efficacy against genotype 3 viruses [49]. For genotype 1 strains,
our results indicate that MK-5172 is highly active against R155K
and D168A variants, while danoprevir is highly active against the
A156T variant and to a lesser extent against the D168A variant.
Thus, as new inhibitors are developed and HCV resistance testing
becomes more available, our findings can help guide anti-HCV
treatment regimens for individual patients.
Figure 5. Stereo view of the vaniprevir complexes. (A) Vaniprevir bound to the wild-type protease with the substrate envelope in blue. Intra-
and inter-molecular hydrogen bond interactions are marked as red and grey dashed lines. Vaniprevir is shown bound to the drug-resistant variants (B)
R155K, (C) D168A and (D) A156T with the transparent coordinates representing the wild-type structure to better highlight the molecular changes of
each mutation. In all cases, catalytic residues are depicted in yellow, the P2 subsite in pink, and the drug molecules in orange.
doi:10.1371/journal.ppat.1002832.g005
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Overall our findings correlate with resistance profiles observed
in clinical isolates. Most protease inhibitors select for R155K
variants in genotype 1a patients as only one nucleotide change is
required [29,30,32,37 42]. Genotype 1b patients presumably have
higher barriers to R155K resistance, requiring two nucleotide
substitutions; thus, mutations at A156 and D168 are more readily
Figure 6. Stereo view of the MK-5172 complexes. (A) MK-5172 bound to the wild-type protease with the substrate envelope in blue. Intra- and
inter-molecular hydrogen bond interactions are marked as red and grey dashed lines. MK-5172 is shown bound to the drug-resistant variants (B)
R155K, (C) D168A and (D) A156T with the transparent coordinates representing the wild-type structure to better highlight the molecular changes of
each mutation. In all cases, catalytic residues are depicted in yellow, the P2 subsite in pink, and the drug molecules in orange.
doi:10.1371/journal.ppat.1002832.g006
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observed in response to protease inhibitor treatment. The
resistance at R155K occurs due to reduced interactions in the
S2 subsite. Telaprevir and other linear ketoamide drugs select for
A156T variants [39 41] by direct steric clashes, while linear (BI
201335) and macrocyclic drugs (danoprevir, vaniprevir, TMC435)
with large P2 moieties select for D168A variants [29,30,32,42] by
disrupting favorable stacking interactions with R155. These data
also support the converse observation that D168A variants are
uncommon in patients treated with telaprevir as the drug can pack
tighter in the S2 subsite. Likewise, A156T variants are uncommon
in patients treated with macrocyclic drugs containing flexible P2
moieties due to drug repacking against the mutated protease
surface [29,30,32,42]. However, drugs such as vaniprevir and
MK-5172 containing P2 P4 cyclization likely select for the A156T
variant due to the rigidity of their P2 moieties. Whether A156T
variants will be found in clinical isolates, however, depends on
additional viral factors, such as relative differences in viral fitness
between A156T variants and other competing viral variants. Our
data thus provide a unique resource for preemptively predicting
resistance and choosing the most appropriate protease inhibitor to
treat HCV depending on the resistance profile of a particular
patient viral population. Whether or not specific mutations arise in
clinical isolates is ultimately determined by the complex interplay
between drug potency, viral fitness, and genetic barriers to
resistance. Thus, depending on the initial viral species altered
pathways to resistance will exist.
The crystal structures of these NS3/4A inhibitors also provide a
key resource to guide future strategies in drug design. The high
potency of MK-5172, for example, derives from interactions with
the essential catalytic triad residues, which cannot mutate without
severely disrupting viral fitness. In addition, flexible P2 drug
moieties lacking P2 P4 macrocycles mitigate losses in potency
to the A156T and D168A mutations. Similar chemical features
can be incorporated in future drugs to potentially evade resistance.
Specifically, novel protease inhibitors that incorporate flexible P2
moieties, such as quinoxaline or similar groups, could exploit
interactions with the essential catalytic residues and concurrently
minimize contact with the P2 subsite, thereby reducing their sensi-
tivities to mutations at R155, D168 and A156T. Thus, our
findings suggest strategies for developing protease inhibitors that
retain activity against a wider spectrum of drug-resistant HCV
variants.
Materials and Methods
Inhibitor synthesis
Danoprevir, vaniprevir and MK-5172 were synthesized in
house following reported methods; danoprevir was prepared using
our convergent reaction sequence as described [43]; vaniprevir
and MK-5172 were prepared following the synthetic methods
reported by McCauley et al. [50] and Harper et al. [27],
respectively, with minor modifications. Telaprevir was purchased
from A ChemTek, Inc. (Worcester, MA).
Mutagenesis and gene information
The HCV genotype 1a NS3/4A protease gene described in a
Bristol-Meyers Squibb patent [51] was synthesized by GenScript
and cloned into the pET28a expression vector (Novagen). This
highly soluble single-chain construct of the genotype 1a NS3/4A
protease domain contains a fragment of the cofactor NS4A
covalently linked at the N-terminus [51]. A similar protease
construct exhibited catalytic activity comparable to that of the
authentic full-length protein [52]. All protease variants were
generated using the QuikChange Site-Directed Mutagenesis Kit
from Stratagene. The codon-optimized genotype 1a helicase
sequence (H77c) was cloned downstream to the protease gene to
generate the full-length protease construct. Geneious [53] was
used to generate the sequence alignment of the NS3/4A protease
domain from HCV genotypes 1 6.
Drug susceptibility assays
Single mutations (R155K, D168A, or A156T) were introduced
into the NS3 region of genotype 1a HCV Con1 luciferase reporter
replicon using the mega-primer method of mutagenesis [54].
Replicon RNA of each protease variant was introduced into Huh7
cells by electroporation. Replication was then assessed in the
presence of increasing concentrations of protease inhibitors
(telaprevir, danoprevir, vaniprevir or MK-5172) by measuring
luciferase activity (relative light units) 96 hours after electropora-
tion. The drug concentrations required to inhibit replicon
replication by 50% (IC50) were calculated directly from the drug
inhibition curves.
Enzyme inhibition assays
For enzyme inhibition experiments, 5 nM of the genotype 1a
HCV NS3/4A protease domain was incubated with increasing
drug concentrations for 15 min (90 min for telaprevir) in 50 mM
Tris assay buffer (5% glycerol, 5 mM TCEP, 6 mM LDAO and
4% DMSO, pH 7.5). Proteolysis reactions were initiated by
adding 100 nM HCV NS3/4A substrate [Ac-DE-Dap(QXL520)-
EE-Abu-y-[COO]AS-C(5-FAMsp)-NH2] (AnaSpec) and moni-
tored using the EnVision plate reader (Perkin Elmer) at excitation
and emission wavelengths of 485 nm and 530 nm, respectively.
The initial cleavage velocities were determined from sections of the
progress curves corresponding to less than 15% substrate cleavage.
Apparent inhibition constants (Ki) were obtained by nonlinear
regression fitting to the Morrison equation of initial velocity versus
inhibitor concentration using Prism 5 (GraphPad Software). Data
for each drug were generated in triplicate and processed
independently to calculate the average inhibition constant and
standard deviation.
Expression and purification of NS3/4A protease
constructs
Protein expression and purification were carried out as
described [51,55]. Briefly, transformed BL21 (DE3) E. coli cells
were grown at 37uC and induced at an optical density of 0.6 by
adding 1 mM IPTG. Cells were harvested after 5 hours of
expression, pelleted, and frozen at 80uC for storage. Cell pellets
were thawed, resuspended in 5 mL/g of resuspension buffer
(50 mM phosphate buffer, 500 mM NaCl, 10% glycerol, 2 mM b-
ME, pH 7.5) and lysed with a cell disruptor. The soluble fraction
was retained, applied to a nickel column (Qiagen), washed with
resuspension buffer, and eluted with resuspension buffer supple-
mented with 200 mM imidazole. The eluent was dialyzed
overnight (MWCO 10 kD) to remove the imidazole, and the
His-tag was simultaneously removed with thrombin treatment.
Figure 7. Drug interactions with wild-type and mutant complexes by residue. The Van der Waals contact energy indexes for the wild-type
protease and mutant variants R155K, D168A and A156T are shown by protease residue for (A) telaprevir, (B) danoprevir, (C) vaniprevir and (D) MK-
5172.
doi:10.1371/journal.ppat.1002832.g007
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The nickel-purified protein was then flash-frozen and stored at
80uC.
Crystallization of inhibitor complexes
The above-mentioned protein solution was thawed, concen-
trated to 3 mg/mL and loaded on a HiLoad Superdex75 16/
60 column equilibrated with gel filtration buffer (25 mM MES,
500 mM NaCl, 10% glycerol, 30 mM zinc chloride, and 2 mM
DTT, pH 6.5). The protease fractions were pooled and
concentrated to 20 25 mg/mL with an Amicon Ultra-15
10 kD device (Millipore). The concentrated samples were
incubated for 1 hour with 1 3 molar excess of inhibitor.
Diffraction-quality crystals were obtained overnight by mixing
equal volume of concentrated protein solution with precipitant
solution (20 26% PEG-3350, 0.1 M sodium MES buffer, 4%
ammonium sulfate, pH 6.5) in 24-well VDX hanging drop trays.
Crystallization, data collection and structure solution
X-ray diffraction data were collected at Advanced Photon
Source LS-CAT 21-ID-F, GM/CA-CAT 23-ID-D or with the
in-house RAXIS IV X-ray system. Diffraction intensities were
indexed, integrated and scaled using the program HKL2000
[56]. All structure solutions were generated using simple
isomorphous molecular replacement with PHASER [57]. The
B chain model of viral substrate product 4A4B (3M5M) [43] was
used as the starting model for all structure solutions. Initial
refinement was carried out in the absence of modeled ligand,
which was subsequently built in during later stages of refinement.
Subsequent crystallographic refinement was carried out within
the CCP4 program suite, with iterative rounds of TLS and
restrained refinement until convergence was achieved [58]. The
protein crystals of the wild-type protease and drug-resistant
variants R155K and D168A in complex with MK-5172 grew as
pseudo-merohedral twins. Amplitude-based twinned refinement
was carried out during restrained refinement for all pseudo-
merohedral twins. The final structures were evaluated with
MolProbity [59] prior to deposition in the Protein Data Bank.
To limit the possibility of model bias throughout the refinement
process, 5% of the data were reserved for the free R-value
calculation [60]. Interactive model building and electron density
viewing was carried out using the program COOT [61].
Fobs Fcalc ligand omit maps were generated with the ligand
excluded from the phase calculation using the program PHENIX
[62].
Inhibitor complex analysis
Superpositions were performed in PyMOL [63] using the Ca
atoms of the active site protease residues 137 139 and 154 160.
The wild-type-danoprevir complex was used as the reference
structure for each alignment. The NS3/4A viral substrate
envelope was computed as described using the full-length NS3/
4A structure (1CU1) [64] and product complexes 4A4B (3M5M),
4B5A (3M5N) and 5A5B (3M5O) [43].
Van der Waals contact energy
Van der Waals contact energies between protease residues and
peptide products were computed using a simplified Lennard-Jones
potential as described [65]. Briefly, the Lennard-Jones potential (Vr)
was calculated for each protease-drug atom pair where r, e and s
represent the interatomic distance, vdW well depth, and atomic
diameter, respectively:
Vr 4 e
s
r
 12
{
s
r
 6 
Vr was computed for all possible protease-drug atom pairs within
5 A˚, and potentials for non-bonded pairs separated by less than the
distance at the minimum potential were equated to e.
Supporting Information
Figure S1 Ligand omit maps for protease-inhibitor
complexes. The NS3/4A wild-type protease (grey cartoon) is
shown with inhibitors (orange sticks): (A) telaprevir, (B) danoprevir,
(C) vaniprevir and (D) MK-5172. The electron density maps (blue)
depict the Fobs Fcalc ligand omit maps contoured at 1s.
(TIF)
Figure S2 Sequence alignment of the NS3/4A protease
domain for HCV genotypes 1–6. Consensus sequence (1a
M62321) of NS3/4A protease domain is shown in grey. Amino
acid residues in disagreement are highlighted in color. Residues at
positions 155 and 156 are conserved across genotypes; however,
genotype 3 shows divergence from the consensus at amino acid
168.
(TIF)
Table S1 Drug hydrogen bonds and vdW contacts with
wild-type protease.
(DOC)
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Appendix D
Secondary Contribution 2: Evaluating the role of
macrocyclization in HCV protease inhibitor
resistance
4.1 Secondary Contribution
Author contributions: DS expressed and purified, various protease used in this study.
Additionally, DS participated in experimental troubleshooting as well as manuscript prepa-
ration.
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